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ABSTRACT 
CONFORMATIONAL DYNAMICS LEADING TO ACTIVATION OF THE 
TRANSGLUTAMINASE FACTOR XIII 
Richard Tatum Woofter II 
16 December 2011 
One of the last events that occurs during blood coagulation, a process 
taken for granted on a daily basis, involves Factor XIII (FXIII) cross-linking fibrin 
monomers to form an insoluble clot. In plasma, FXIII-A2 is not active and exists 
as the heterotetramer FXIII-A2B2. Through the utilization of hydrogen -
deuterium exchange (HDX) coupled with Matrix Assisted Laser Desorption 
ionization - Time of Flight - Mass Spectrometry (MALDI-TOF-MS), it was 
determined that FXIII-A2 becomes nearly uniformly protected when bound to 
FXIII-B2 and the FXIII-A2 ~-barrels playa major role in heterotetramer formation. 
After dissociation from FXIII-B2, FXIII-A2 has the ability to become 
activated in the presence of Ca2+. The regions/residues of FXIII-A2 Ca2+ affects 
during activation were identified using HDX. It is debated whether FXIII-A2 
undergoes an open conformation during activation. Transglutaminase 2 (TG2) 
has been observed crystallographically in an open conformation. HDX was 
utilized to compare the conformational dynamics of Transglutaminase 2 in 
solution to that of FXIII-A2. The increase in exposure between the catalytic core 
and ~-barrels of TG2 yields evidence of an open conformation. A structural 
vi 
comparison of FXIII-A2 and TG2 identified steric hinderance within the A2 dimer 
that could thwart a similar conformational change. 
Once activated physiologically, FXIII-A2 is solely responsible for forming 
the cross-links between fibrin monomers. The aC (233 - 425) region of fibrin 
contains three reactive Gin residues and acts as a substrate for FXIII. Fibrin aC 
(233 - 425) was expressed and its structure investigated via 15N-HSQC when in 
solution with FXIII-A2. 
The integral role of FXIII-A2 in the coagulation cascade leads to a dire 
need for investigating its conformational dynamics during activation. The 
research herein provides a stronger knowledge of FXIII-A2 structural changes 
during activation and outlines FXIII-A2 interactions with 82 and the fibrin aC 
domain. This progress in understanding FXIII-A2 dynamics could lead to 
improved treatments for excessive bleeding and thrombosis. 
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Blood Coagulation Overview 
CHAPTER I 
INTRODUCTION 
The highway system that transports nutrients to all cells within the body 
and aids in eliminating cellular waste is referred to as the circulatory system. The 
circulatory system involves many organ systems working in harmony with one 
another. The organ that acts as the carrier for all the nutrients, amino acids, 
hormones and cellular waste is blood (1). If there is a breach in the vasculature 
there needs to be processes in place which quickly and efficiently close the 
breach while not allowing for any disturbance in the flow of blood (nutrients) to 
cells throughout the body. Haemostasis ('hemo' = blood + 'stasis' = stagnation), 
the process of stopping blood flow in damaged tissue, starts with 
vasoconstriction to slow the flow of blood to the damaged area. This 
physiological process can also be assisted by external pressure on wounded 
tissue. Following vasoconstriction, platelets are recruited to the damaged tissue 
to form a plug. As the platelets aggregate, tissue factors signal the coagulation 
cascade which ultimately concludes in a soluble fibrin clot being crosslinked by 
factor XIII (FXIII) to form an insoluble clot (1) .. 
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Historically it was believed 
that coagulation was initiated after 
an injury when blood was exposed 
to air. It was not until the mid-19th 
century before it was proposed that 
a specific component in the blood 
initiated coagulation (2). Nearly a 
century later in 1964, the "Cascade" 
or "Waterfall" model was released 
by two independent groups (3-4). 
These models were developed 
under the premise of defining the 
Contact Factor Pathway 
Intrinsic Pathway 
Tissue Factor Pathway 
Extrinsic Pathway 
XII -VII-'-X"l.~ TIssuer:: 








Fibrinogen Fibrin Monomer 
! 
Soft Fibrin Clot 
Xlll~Xmac;;;:-+ ! 
Hard Fibrin Clot 
Figure 1: The conventional V-shaped cascade 
model of coagulation. This model initiates via the 
Intrinsic (contact factor) pathway or the extrinsic 
(tissue factor) pathway. This diagram was adapted 
from a poster distributed by Enzyme Research 
Laboratories, South Bend, IN. 
identity and function of the procoagulant enzymes. The early models involved 
the familiar Y -shaped scheme (Figure 1 or for more detail Appendix A) where the 
"intrinsic" and "extrinsic" pathways converged in a common pathway with the 
production of Factor Xa After several decades of discoveries, questions started 
to arise concerning the independent nature of the intrinsic and extrinsic 
pathways. One such question being, why do patients with a deficiency of FVIII 
and FIX (see appendix B for coagulation enzyme abbreviations) in the "intrinsic" 
pathway contract hemophilia A and B respectively when they still have an intact 
"extrinsic" pathway(5). Hoffman and Monroe have since worked to develop a 
model in which coagulation is mediated by the cell surfaces where they occur. 
They propose a model that incorporates three overlapping stages: 1- initiation, 
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occurring on tissue factor baring cells; 2-amplification, occurs when platelets and 
cofactors become activated prior to thrombin production; and 3- propagation, 
where large amounts of thrombin are generated on the platelet surface (6). 
Initiation 
Tissue factor (TF) is an integral membrane protein that plays the role of 
initiator in coagulation in vivo. As a membrane bound protein, TF remains 
localized to the cell in which it was synthesized and these cells are generally 
located outside the vasculature (7). Once there is a breach in the vessel, blood 
will come into contact with the TF-bearing extravascular cells. FVII is easily 
activated by coagulation and non-coagulation proteases and rapidly binds to 
cellular TF. The FVlla-TF complex then goes on to further activate more FVII as 
well as both FX and FIX. The FX that is activated by the FVIIA-TF complex is 
quickly degraded if it leaves the cell surface, but when it remains within the 
confines of the forming thrombus, it can combine with FVa to produce thrombin 
which will aid in activating platelets and FVIII during amplification (8). 
Amplification 
The next step is to amplify the coagulation response that was just initiated. 
The damage to the endothelium that initiated the response also allows platelets 
to come in contact with TF-bearing cells. The thrombin that was produced during 
the last stages of initiation is then utilized to enhance platelet adhesion and 
activation (9). Thrombin also assists in preparing for procoagulant activity by 





Figure 2: The Cell-Based Model of Hemostasis. In the cell based model, several cell surfaces are utilized in 
during the series of events that lead to a fibrin clot. (A) During the Initiation phase TF-bearing cells become 
exposed to plasma after injury and FIXa and lIa are released and diffuse to the platelet surface. (8) During 
Amplification the lIa released on the TF-bearing surface serves to activate the platelets and FXI as well as 
release vWF yielding FVllla. (C) During Propagation several of the enzymes that were activated earlier 
assemble on the surface of the activated platelet. FIXa/FVlla form the tenase which aid in FXa formation . 
FXa/FVa then form prothrombinase which results in the burst of lIa. lIa then goes on to cleave fibrinogen and 
activate FXIII which crosslinks the fibrin to form an insoluble clot. Figure adapted from cell-based hemostasis 
models (2, 6) . 
Thrombin continues its action by activating platelets through the utilization 
of their protease-activated receptors (PAR) (10) . FV is released from platelets 
and subsequently activated by thrombin . Some of the thrombin remains on the 
surface of the platelet and is available for cleaving other coagulation enzymes. 
von Willebrand factor (vWF)/FVIII circulate together and when bound to the 
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platelet surface, thrombin activates the FVIII through the release of vWF (11). 
The amplification process has now produced activated platelets with activated 
cofactors such as FVa, FVllla and FXla on their surfaces; therefore, propagation 
is ready to commence. 
Propagation 
The FIXa and FVllla that were activated during initiation and propagation 
respectively are now poised to form the intrinsic tenase complex on the surface 
of activated platelets. Once FIXa diffuses from the TF-bearing cell to the platelet 
these complexes begin to form. In addition to FIXa diffusing from the 
neighboring TF-bearing cell, it can also be activated on the platelet surface by 
FXla (12). The tenase complexes then continue the coagulation processes by 
activating FX on the platelet surface where it is poised to complex with FVa. 
These FXa/FVa "prothrombinase" complexes convert II to lIa generating a lIa 
burst (6). 
The lIa generated during initiation, amplification and propagation is further 
utilized in clot stabilization. Fibrinogen is a 340 kDa protein that consists of three 
chains (Aa, B~ and y) forming the homodimer (AaB~Yh.Thrombin converts 
fibrinogen to fibrin through the cleavage of fibrinopeptides A and B. Fibrin then 
non-covalently self associates in the formation of a soft clot (13). The soluble 
fibrin clot is then stabilized through y-glutamyl-E-Iysinyl cross-links formed 
between the fibrin y - y and y - a chains by lIa-activated FXIII (14). Thrombin 
activated FXIII further stabilizes and protects the growing fibrin network from lysis 
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by cross-linking it to thrombin-activatable fibrinolysis inhibitor (TAFI) and a2 
antiplasmin (a2AP) (15-17) . 
The process of haemostasis has been broken down into three overlapping 
stages: Initiation, Amplification, and Propagation. Of the many enzymes and 
cofactors involved, the research presented here focuses FXIII. The use of 
techniques such as HDX coupled with MALDI-TOF-MS aim to shed light into the 
illusive FXIII conformational changes. 
Transglutaminase Factor XIII 
FXIII-A2 has gained much 
interest over the last couple 
decades due to its presence in the 
cytoplasm of several different cell 
types: macrophages, 
megakaryocytes, and connective 
tissue histiocytes to name a few 
(19-21). Factor XIII plays an 
Activation Peptide 
Figure 3: Labeled FXIII-A (1 FIE) This figure was 
made using PyMol(18) . 
integral role in the coagulation cascade, and there is much need to investigate 
the conditions that affect activation/activity as well as the structural dynamics of 
the enzyme during activation. A better understanding of the structural changes 
around the active site of FXIII during activation, as well as how it interacts with 
the other enzymes and proteins involved in the coagulation cascade, could lead 
to more targeted therapeutic agents for treatment of excessive bleeding, 
thrombosis, and atherosclerosis. 
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The action of Factor XIII was first reported in the early 1920s when Barkan 
and Gaspar observed that fibrin clots formed in the presence of Ca2+ were 
insoluble in weak bases (22) . Over 25 years later in a letter to Nature, Lorand 
reported that a protein was responsible for the formation of insoluble clots 
because the "fibrin stabilizing factor" was thermolabile, nondialyzable and 
required Ca2+ (23). Then after the acknowledgement of fibrin stabilizing factor as 
a clotting factor in 1963 by the International Committee on Blood Clotting 
Factors, it became factor XIII (24). It soon became obvious that FXIII was 
essential for stabilizing the non-covalent soft clots formed in blood coagulation 
after thrombin cleaves the A and B fibrinopeptides from fibrinogen. 
Factor XIII is a protransglutaminase in plasma with a tetrameric structure 
consisting of two A subunits and two B subunits (FXIII-A2B2). The details of 
FXIII-B will be further discussed in chapter IV, but briefly, all FXIII-A in plasma is 
found bound to FXIII-B as a FXIII-A2B2 heterotetramer with an appearant Kd of 
25 nM (25) . In platelets, FXIII-A2 is found without the B2 dimer and is referred to 
as cellular FXIII (26) . The -83 kDa factor XII I-A has been successfully 
expressed and the recombinant form, rFXII I, has been subsequently crystallized 
(27). The crystal structure illustrates the wel l-defined and sequentially folded 
domains: the activation peptide (1-37) , the ~-sandwich (38-184) , the catalytic 
core (185-515) , ~-barreI1 (516-628), and ~-barreI2 (629-730) (Figure 3). 
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A ~A Thrombin If A " Low mM Ca" B 
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Figure 4: Factor XIII activation scheme. A) Plasma FXII I activation. Intact FXIII-A2B2, thrombin cleaved 
FXIII-A', Ca2+ induced dissociation of FXIII-A2 and FXIII-B2 yeilding active FXIII-A" (FXllla"a) . 8 - D) 
Cellular FXIII-A2 activation. 8) Thrombin proteolytic activated FXIII-A2, thrombin cleaved FXIII-A' and fully 
active FXIII-A" (FXllla"a) in the presence of low mM Ca2+. C) FXIII-A2 nonproteolytic activation in the 
presence of high (50 mM) [Ca2+] FXIII-A" (FXlllaca) D) FXIII-A2. nonproteolytic activation in the presence of 
low mM Ca2+ and high (> 150 mM) NaCI yielding FXIII-Ao (FXlllaNa) . 
When FXIII is activated physiologically (Figure 4) , thrombin (lIa) cleaves 
the N-terminal activation peptide (residues 1-37). Following activation peptide 
cleavage, both low mM Ca2+ and the C-terminal portion of the fibrin a-chain 
assists in the dissociation of the two B subunits (28-32). Once the FXIII-A2 is free 
from FXIII-B2 it is active (FXllla lla). Factor XIII exists as a dimer and the active 
site consists of a catalytic triad (C314 , H373 and D396). The catalytic C314 has an 
apparent pKa of 6.0, similar to that of a histid ine imidazole (33) . The hydroxyl 
oxygen of Y560 forms a hydrogen bond with C314 (27) . This H-bonding 
interaction is indicative of a thiolate - imidazolium pair (34) . The catalytic sulfur 
anion is stabilized at physiological pH through the H-bonding with Y560 and ion-
pair interactions with the H373 imidazolium (27, 34-35) . 
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Oimer formation is important for the stability of FXIII-A. The dimer 
interface covers 2280 A2 and there is a 10.3 - 14.4 kcal/mol decrease in its free 
energy upon dimerization (36). When in the presence of a suitable acyl-donor 
glutamine containing substrate, C314 of FXllla forms a thioester bond and 
ammonia is released. The acyl-donor substrate is then covalently linked to a 
primary amine (lysine) acyl-acceptor forming v-glutamyl-E-Iysine cross-links 
between the a- and v-chains of fibrin which stabilizes the growing clot. In 
addition to clot stabilization, FXIII also assists in protecting the clot from plasmin 
degradation via crosslinks between the Aa-chain of fibrin and a2 antiplasmin( 15, 
17,37). 
FXIII can also be non-proteolytically activated (Figure 4 C and D) when 
the Ca2+ concentration is greater than 50 mM (FXlllaca) (38-39). Under these 
non-physiological conditions the activation peptide is not cleaved and the 
enzyme shows activity. Another nonproteolytic activation mechanism has been 
demonstrated that is more physiologically relevant. When the factor XIII-A2 
subunits are in the presence of 150mM Na+ with low mM Ca2+ (FXlllaNa), albeit 
slow, transglutaminase activity is observed (40). When haemostasis concludes, 
one means that FXIII-A2 can be rendered inactive is through cleavage at the 
secondary cleavage site (K513-S514). 
Hydorgen Deuterium Exchange (HDX) Coupled with Mass Spectrometry 
The major theme underlying this research is establishing the 
conformational dynamics of FXIII-A2 in solution. The FXIII-A2 crystal structures 
provided to date for zymogen (27), FXlilalia (41), and FXlllaca (42) display no 
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significant RMSO between the activated and unactivated forms. The active site 
is occluded in all crystal structures so an active conformation has yet to be 
observed. In an effort to gain a better understanding of FXIII-A2 during 
activation, HOX has been utilized in several studies (43-46). HOX has proved to 
be a worthy method of isolating structural changes to defined regions of the 
molecule 
Proteins in solution are not static and in fact are naturally moving, flexing, 
and possibly even opening and closing. These movements termed, 
conformational dynamics, are difficult to monitor and impossible to see via 
crystallography. One benefit of HOX in the field of protein dynamics is the 
needed sample size. A typical HOX sample contains 12 IJI of 30 - 50 IJM protein 
whereas NMR would require approximately 350 IJI and preferably> 100 IJM 
protein. At pH 7.0 exposed protein backbone amide hydrogens exchange with 
0 20 within 1 - 10 seconds (47). Within the interior of the protein, exchange is 
limited because there is not only restricted access but also nearly all amide 
hydrogens are involved in hydrogen bonds. The H-bonding protects the 
hydrogen from exchange (48). When running HOX at physiological pH, base-
catalyzed exchange is the dominant mechanism of hydrogen exchange. This 
occurs in the presence of a catalyst (hydroxide) and a new hydrogen (water) 
(47). 
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The rate of hydrogen 
exchange in an unfolded protein is 
dependent upon several factors. 
In Equation 1, U and F represent 
Equation 1: Rate Constants for hydrogen-deuterium 
exchange where F and U represent folded and unfolded 
protein respectively (47). 
the unfolded and folded protein respectively; therefore, hydrogen-deuterium 
exchange is not only dependent upon (k2) , but also the k1 and k1 (the unfolding 
and folding of the protein). The exchange kinetics are broken down into two 
pathways, EX1 and EX2 kinetics. When k2» k1 EX1 kinetics ensue. Under 
EX1 kinetics, there is an unfolding event and the residues involved are 
exchanged prior to refolding. This is very rarely seen naturally, without 
denaturants. Therefore, EX2 kinetics typically prevail where the protein is quickly 
exchanging between two states and the refolding rate is faster than the exchange 
rate (k1 »k2)' Once hydrogen-deuterium exchange occurs, the half-life for 
amides increases to over an hour by lowering the pH to between 2 and 3 at 0 °C 
(48). This low pH -low temperature quench allows for protein digestion and 
mass spectrometric analysis. 
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Figure 5: Schematic describing the processes involved in hydrogen-deuterium exchange coupled with 
MALDI-TOF-MS. The details are in-text. 
The details of the method used for each HDX experiment are explained in 
the methods section of each respective chapter, Figure 5 is a pictorial 
representation to assist in visualizing the process. The starting material is a 
lyophilized protein containing hydrogens (blue circles) at all amide linkages. The 
protein is resuspended in 0 20, introducing the protein to a deuterium (red circles) 
environment. During the 10 minute room temperature incubation, the hydrogens 
are given time to exchange with the deuterons as described by the kinetic regime 
presented above. To quench the exchange, samples were placed on ice and 
trifluoroacetic acid was added dropping the pH to 2.2. The protease utilized was 
pepsin due to its ability to function at low pH. After 10 min, aliquots of the peptic 
digestion were quick-frozen in liquid nitrogen and stored cryogenically until analysis. 
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Matrix was added to the sample spotted on MALOI plates for analysis. The 
spectra in Figure 5 are a representative FXIII-A2 pepsin digest. The three 
spectrum labeled A, Band C represent an undeuterated spectra (A), and two 
different states (B) and (C) where (C) displays the highest level of deuterium 
incorporation or exposure. 
Hydrogen-deuterium exchange coupled with mass spectrometry provides 
an extremely powerful tool to analyze the conformational dynamics of proteins in 
solution. In the research presented HOX has successfully identified regions of 
FXIII that experience protection or exposure due to physiological Ca2+ 
concentrations, as well as after non-proteolytic activation. To approach the 
question of whether FXIII-A2 adopts an open conformation when activated, FXIII-
A2 HOX was compared to transglutaminase 2 (TG2), an enzyme with the same 
domain structure as FXIII, in both an open and closed conformation. Lastly, the 
interface between FXIII-A2 and FXIII-B2 is not well defined and HOX has 




FXIII-A2 solution conformational dynamics is the basis of all research 
presented in this dissertation. The overarching goal is to gain a better 
understanding of the solution structure of FXIII-A and understand how it interacts 
with substrate. HDX was the primary method for studying FXIII-A conformational 
dynamics, but NMR was utilized in analyzing aC (233 - 425) structure in solution 
with FXIII-A2 (described in chapter V). 
In Chapter II, the FXIII-A2 conformational dynamics journey starts by 
investigating the solution structure of FXIII-A2 in the presence of physiological 
Ca2+ (1 mM)(44). To determine whether the conformational changes seen in the 
presence of Ca2+ were Ca2+ specific, Mg2+, 8a2+ and Cu2+ were also investigated. 
Non-proteolytically Ca2+ activated FXlllaca was also analyzed by HDX and 
compared to FXlllaNa. These HDX studies led to many new discoveries 
concerning the Ca2+ specific conformational dynamics of FXIII-A2 both before (1 
mM Ca2+) and after activation. 
After Pinkas et al. reported that the transglutaminase TG2 could be 
trapped in an open conformation (49), HDX was utilized to determine if FXIII 
assumed a similar open conformation. Chapter III describes the conformational 
dynamics of TG2 in the activated state and also in the open state after inhibition 
with TG-DON. HDX has already been used to analyze FXIII-A2 in the activated 
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state (Chapter II) and inhibited with the substrate peptide Kg-Don (43). TG2 
conformational dynamics have yet to be investigated by HDX and these analyses 
allow for a great comparison for FXIII-A to a known 'open' conformation. 
The previous studies focused on the conformational dynamics of FXIII 
during the last phases of activation. Chapter IV took a step backward in the 
activation process to investigate the interaction between FXIII-A2 and FXIIIB-2. 
The FXIII-A2B2 heterotetramer plays a major role physiologically but the interface 
between the FXIII-A and FXIII-B subunits is not very well understood. HDX once 
again proved to be an invaluable tool in determining the regions of FXIII-A2 that 
become protected when bound to FXIII-B2. 
When studying protein conformational dynamics, it is beneficial to 
establish an expression system for your protein of interest. The development of 
an expression system opens the doors to introducing mutations and/or the 
incorporation of isotopic labels for NMR analysis. The aC domain of fibrin is 
known to interact with FXIII-A2B2 and the aC (242 - 424) region aids in the 
dissociation of FXIII-A2B2 (28). Chapter V describes the expression system 
established and utilized to express 15N_ aC (:233 - 425). The 15N-labeled aC was 
then analyzed via 15N-HSQC to determine if lit adopted any compact structure 
when interacting with FXIII-A2. 
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CHAPTER II 
ROLE OF CALCIUM IN THE CONFORMATIONAL DYNAMICS OF FACTOR XIII 
ACTIVATION EXAMINED BY HYDROGEN/DEUTERIUM EXCHANGE 
COUPLED WITH MALDI-TOF MS 
Introduction 
Due to the critical role of FXIII in coagulation, there is a need to better 
understand the conditions that influence FXIII activation/activity as well as the 
structural dynamics of this enzyme system. Recombinant FXIII A2 has been 
successfully crystallized (27), and the resultant structure exhibits well-defined 
and sequentially folded domains that include the activation peptide (1-37), the ~ 
sandwich (38-184), the catalytic core (185-515), ~-barreI1 (516-628), and ~­
barrel 2 (629-730) Figure 6. 
When FXIII is activated physiologically, thrombin (lIa) cleaves the N-
terminal activation peptide (residues 1-37). The presence of low mM Ca2+ 
assists in the dissociation of the B subunits from plasma FXIII. In addition, Ca2+ 
promotes exposure of the catalytic C314 from both plasma and cellular FXIII 
resulting in an active A2 dimer (FXllla*) (26, 30, 32). Like other 
transglutaminases (TGases), the active site of FXIII consists of a thiol-containing 
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catalytic triad (C314, H373, and 0396) , but FXIII is unique in the fact that it exists 
as a dimer. 
Figure 6: The FXII I A2 zymogen 2.1 crystal structure 1 F13 (50) . (A) A cartoon model to illustrate the 
intimate contact at the dimer interface with the domains being color coded (grey) activation peptide, 
(white)I3-Sandwich , (black) catalytic core, (white) l3-barrel 1 and (black) l3-barrel 2. (8) Ribbon view of one 
FXIII-A monomer with the domains represented by the same colors as (A) . The regions of interest are 
labeled: activation peptide (1-37), Gin recognition peptide 4 (72-97), Gin recognition peptide 7 (190-230), 
catalytic triad (314, 373 and 396) , Tyrosine 560, secondary cleavage site (513-514) and the proposed lysine 
recognition reg ion (646-658). These figures were created using VMD (51). 
In addition to Iia proteolytic activation, FXIII A2 can be non-proteolytically 
activated when the Ca2+ concentration is greater than 50 mM (FXllla O or FXlllaca) 
(38-39) . FXIII A2 has also been observed in an activated state in the presence of 
>150 mM NaCI and low mM Ca2+ (FXlllaNa) (40) . A related form of nonproteolytic 
FXIII activation has been documented in platelets (40, 52-53). Thrombin-
stimulated platelets may exhibit increased Ca2+ levels that promote formation of 
an active intracellular FXIII species which has not been hydrolyzed at the R37-
G38 peptide bond. In plasma, these different forms of nonproteolytic activation 
are minimized by the presence of the B2 subunits (54) . Regardless of the mode 
of activation, FXllla function can be hindered following hydrolysis at the 
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secondary cleavage site (K513-S514) by thrombin (55-56). Occupation of a 
nearby site with Ca2+ and other select metals can help protect this secondary 
hydrolysis from occurring (27, 57). 
Even though the catalytic C314 is only alkylated by iodoacetamide (IAA) 
after activation, (33, 58-59) the crystal structures for FXllialia and FXlllaca lack 
any major structural changes when compared to that of zymogen (27, 41-42). 
The Maurer lab has used MALDI-TOF mass spectrometry approaches coupled 
with hydrogen-deuterium exchange or chemical modification to probe FXIII 
conformation changes occurring in solution. During activation, portions of the 
FXIII catalytic core and the A2 dimer interface were found to be more accessible 
to solvent (45, 60). By contrast, the addition of an inhibitory peptide with a 
glutamine isostere caused selected FXIII regions to become more protected from 
solvent (43). As expected from the secondary cleavage studies, Ca2+ binding 
hindered solvent exposure in a FXIII segment around 513-514. Inhibition at the 
active site could lead to further long-range decreases in HDX in this region. 
A recent paper by Kristiansen and Andersen questions our use of borate 
buffer supplemented with CaCI2 for mass spectrometry based projects. Our HDX 
studies have not, however, been carried out under deactivated concentrations 
(0.3 mM CaCI2) as they presume, but at 1 mM CaCI2 following either proteolytic 
or nonproteolytic activation. According to their paper, FXIII A2 that is activated 
nonproteolytically at 50 mM CaCb and then buffer exchanged into 1 mM CaCI2 
maintains 90% of its enzyme activity (61). Moreover, many of the 
conformational events reported as being important for FXIII activation have been 
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confirmed by HDX studies by Andersen and Faber using a buffer system of 200 
mM Hepes, 150 mM NaCl, and 50 mM CaCI2 (46). 
The focus of our present HDX work was to further investigate the 
conformational changes that occur to FXIII due to monovalent and divalent cation 
binding. FXIII A2 was monitored in the presence of Ca2+, Mg2+, 8a2+, Cu2+, Na+, 
tetramethylammonium chloride (TMAC+) or ethylenediamine (EDA2+) with 
concentrations ranging from physiological Ca2+ concentration, 1-2 mM, up to 50-
500 mM. On its own, the low mM Ca2+ condition is unable to support FXIII 
activity. The HDX effects observed in this environment thus provide valuable 
information on early conformational changes needed in preparation for activation. 
Often these effects further increased as the Ca2+ concentration was raised to the 
levels required for nonproteolytic activation (50-500 mM). Several of the 
conformational changes observed with physiological 1 mM Ca2+ also occurred 
with the other divalent metals whereas other effects were distinct for a particular 
metal. In the current investigation, a novel method of nonproteolytic FXIII 
activation was characterized utilizing high concentrations of organic cations 
TMAC+ or EDA2+. Knowledge gained from these different HDX studies will help 
identify the elusive structural roles of different divalent and monovalent cations. 
A greater understanding of the conformational dynamics of FXIII will aid in the 
development of new therapeutic strategies to control excessive bleeding, 
thrombosis, and/or atherosclerosis. 
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Materials and Methods 
Factor XIII Preparation and Synthetic Peptides 
Recombinant human cellular factor XIII A2 (FXIII A2) was generously 
provided by Dr. Paul Bishop (ZymoGenetics, Inc., Seattle, WA). After 
reconstituting the lyophilized FXIII in 18 MO deionized water, FXIII was buffer 
exchanged into 6.67 mM borate at pH 8.3. The concentration of FXIII was 
determined on a Cary 100 UV/vis spectrophotometer. The absorbance was 
monitored at 280 nm and concentration calculated with the FXIII extinction 
coefficient of 1.49 mllmg cm. Aliquots (36 1-11) of 16.7 I-IM FXIII in 6.67 mM borate 
were dried in a SpeedVac (Savant) and stored at -70°C until future use. 
The ~ casein derived FXIII substrate peptide K9 (Ac-LGPGQSKVIG-OMe) 
was synthesized by Peptides International (Louisville, KY). K9 was reconstituted 
in 18 MO deionized water and the concentration was confirmed by quantitative 
amino acid analysis (AAA Service Laboratory, Inc., Boring, OR). Purity was 
assessed by HPLC and mass spectrometry approaches. 
Transglutaminase Activity Assay 
Factor XIII activity was determined using a modified version of the Oade-
Behring Berichrom Assay (62-63). Briefly, this assay utilizes a coupled reaction 
involving both FXIII and glutamate dehydrogenase (GOH). FXllla reacts with the 
acyl-donor K9 releasing NH3 and the transglutaminase reaction concludes when 
the primary amine acyl-acceptor, glycine ethyl ester, forms an isopeptide bond 
with the K9 peptide. This transglutaminase activity is monitored via the 
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conversion of a-ketoglutarate and NH3 into glutamate in the presence of reducing 
equivalents of NADH. The oxidation of NADH results in decreased absorbance 
at 340 nm. 
Dry FXIII aliquots were activated nonproteolytically in a total volume of 12 
1-11 dH20. The final working concentration was 50 I-IM FXIII in 20 mM Borate at 
pH 8.3 with 50 mM CaCI2, 50 mM MgCI2 with 2 mM CaCI2, 50mM BaCI2 with 2 
mM CaCb, 50 mM CuCI2 with 2 mM CaCb, 500 mM ethylenediamine (EDA2+) 
with 2 mM CaCI2, 500 mM NaCI with 2 mM CaCI2, and 500 mM 
tetramethylammonium chloride (TMAC+) with 2 mM CaCI2}. FXIII was activated 
for 10 min at 37°C before adding 3 1-11 to the assay. For each assay, the volume 
of activator reagent (163 I-II) and detector reagent (250 I-II) as well as the 
concentration of FXIII (300 nM) and Kg (500 I-IM) were held constant (64). The 
assay contents were placed in a Cary 100 UV/vis spectrophotometer for 2 min at 
37°C for equilibration before the Kg substrate peptide was added. After 
introducing the Kg peptide, the oxidation of NADH was monitored for 25 minutes 
at 340 nm. Due to the coupled nature of this FXIII activity assay, there is a brief 
delay before consumption of NADH can be detected. The FXIII transglutaminase 
activity was later determined by the steepest part of the slope which correlates 
with enzyme catalyzed velocity (~abs/min). The final divalent and monovalent 
cation concentrations in the assays ( 0.3-3 mM) did not interfere with GDH 
reactivity. Using the molar absorptivity value for NADH (6220 M-1cm-1 at 340nm), 
the transglutaminase based velocities were converted into (I-IM/min) and the final 
velocity values compared. For the studies involving the novel cations EDA2+, 
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Na+, and TMAC+, transglutaminase activity was compared relative to that of 
FXlIlCa with % FXlIlCa Activity defined as (FXllla activity I FXlllca) x 100. 
Standard Deviations of the mean for three independent trials were calculated. 
HDX Experimentation 
There were two different groups of HDX samples, one monitoring the 
effects of low mM concentrations of divalent metals and the other examining non-
proteolytic activation. Both groups utilized the dry buffer exchanged FXIII 
aliquots. To probe the effects of low mM divalent metals, 0.6 IJI of 20 mM metal-
chloride (CaCb, MgCI2, BaCI2 or CuCI2) was added to the dry FXIII aliquot and 
evaporated to dryness in the SpeedVac and stored at -70°C. The following HDX 
protocol was then adapted from methodology established in the Komives 
laboratory (65-66). The dry FXIII aliquot was allowed to reach room temp before 
12 IJI of 99.996% D20 (Cambridge Isotope Laboratories) was added yielding a 
final working concentration of 50 IJM FXIII and 1 mM Ca2+, Mg2+, Ba2+ or Cu2+ in 
20 mM Borate at pH 8.3. The samples were incubated at room temperature for 
10 minutes before the HDX was quenched by adding 120 IJI of chilled 0.1% TFA 
at pH 2.5. The quenched reaction was then immediately transferred to a tube 
containing activated pepsin bound to 6% agarose (Thermo Scientific, Rockford, 
IL). Pepsin digestion occurred for 10 min on ice. Following digestion, the 
reaction mix was centrifuged for 30 sec to separate the FXIII digest from the 
pepsin beads. Three 8.2 IJI aliquots were immediately frozen in liquid N2 and 
each reaction condition was performed three times. 
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When investigating nonproteolytically activated FXIII, aliquots were 
prepared as described previously. Divalent and monovalent cations « 3 1-11) were 
added to the dry FXIII aliquot for each of the activation conditions (50 mM Ca2+, 
500 mM ethylenediamine (EDA) with 2 mM Ca2+, 500 mM Na+ with 2 mM Ca2+, 
and 500 mM tetramethylammonium chloride (TMAC+) with 2 mM Ca2+) and 
evaporated to dryness in a SpeedVac and stored at -70°C. After allowing the 
sample to reach room temperature, 12 1-11 99.996% 0 20 was added and the HDX 
occurred at 3TC for 10 min. The activated FXIII was digested and quenched as 
stated above. 
HDX Analysis 
A FXIII(a) HDX aliquot was thawed at room temperature and immediately 
mixed with an equal volume of 10 mg/ml a-cyano-hydroxycinnamic acid matrix 
(a-CHCA) (Aldrich) in 1:1:1 ethanol/CH3CN/0.1%TFA at pH 2.2, and 0.51-11 was 
spotted on a chilled MALDI plate. The sample spot was then quickly dried by 
placing the MALDI plate into a SpeedVac. The plate was then immediately 
inserted into the MALDI-TOF-MS (Voyager DE-Pro, Applied Biosystems). By 
limiting time for this procedure to < 5 min, HDX back exchange is kept at a 
minimum. Spectra were collected in reflector mode with 256 shots/spectrum. All 
peptides in the peptic digest were previously identified by Brian T. Turner, Jr. (45) 
and/or confirmed by MS/MS analysis on an Applied Biosystems 4700. The 
MS/MS peptide identifications were performed using Applied Biosystems GPS 
software which utilized the Mascot database. Peptide identification was 
confirmed through observing the same peptide sequence in multiple independent 
23 
digests, with an ion score preferably above 20 (peptic peptides Appendix C). 
After digestion by pepsin, the FXIII A2 peptides identified represent 40 % 
1 SETSRTAFGG RRAVPPNNSN AAEDDLPTVE LQGVVPRGVN LQEFLNVTSV HLFKERWDTN 60 
61 KVDHHTDKYE NNKLIVRRGQ SFYVQIDFSR PYDPRRDLFR VEYVIGRYPQ ENKGTYIPVP 120 
121 IVSELQSGKW GAKIVMREDR SVRLSIQSSP KCIVGKFRMY VAVWTPYGVL RTSRNPETDT 180 
181 YILFNPWCED DAVYLDNEKE REEYVLNDIG VIFYGEVNDI KTRSWSYGQF EDGILDTCL! 240 
241 VMDRAQMDLS GRGNPIKVSR VGSAMVNAKD DEGVLVGSWD NIYAYGVPPS AWTGSVD~ 300 
301 EYRSSENPVR YGQCWVFAGV FNTFLRCLGI PARIVTNYFS AHDNDANLQM DIFLEEDGNV 360 
361 NSKLTKDSVW NYHCWNEAWM TRPDLPVGFG GWQAVDSTPQ ENSDGMYRCG PASVQAIKHG 420 
421 HVCFQFDAPF VFAEVNSDLI YITAKKDGTH VVENVDATHI GKLIVTKQIG GDGMMDITDT 480 
481 YKFQEGQEEE RLALETALMY GAKKPLNTEG VMKSRSNVDM DFEVENAVLG KDFKLSITFR 540 
541 NNSHNRYTIT AYLSANITFY TGVPKAEFKK ETFDVTLEPL SFKKEAVLIQ AGEYMGQLLE 600 
601 QASLHFFVTA RINETRDVLA KQKSTVLTIP EIIIKVRGTQ VVGSDMTVTV QFTNPLKETL 660 
661 RNVWVHLDGP GVTRPMKKMF REIRPNSTVQ WEEVCRPWVS GHRKLIASMS SDSLRHVYGE 720 
721 LDVQIQRRPS M 
Figure 7: FXIII peptides observed by MALDI-MS after 10 minute pepsin digestion are underlined. The 
underlined peptides represent 40 % coverage. 
coverage (Figure 7). These peptides focus on key FXIII regions found within the 
~-sandwich, the catalytic core, and the ~-barreI1 region. Additional studies with 
acid dependent type XIII protease did not significantly improve sequence 
coverage. All the MALDI spectra derived from pepsin digests were analyzed 
using Data Explorer (Applied Biosystems) and calibrated using two singly 
protonated reference peptides; monoisotopic mass 850.4787 Da (residues 535-
541) and quadraisotopic mass of 1375.7097 Da (residues 220-230). 
Deuterium incorporation for each isotopic cluster was quantified as 
described by Sabo et al. (67). To determine the change in deuteration for FXIII 
under different conditions the percent deuteration for each peptide was 
calculated using equation 1: 
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"difference = (D - Dp::l1 ) x 100 
Dmaxi ; (1) 
where OFXIII is the amount of deuterium incorporated in FXIII zymogen, 0 is the 
amount of deuterium incorporation in FXIII under different conditions and Omax is 
the theoretical maximum amount of deuterium incorporation for the given peptide 
under these conditions. The theoretical maximum depends on the final 
percentage of 0 20 under quench conditions (4.5 %) and accounts for all 
exchangeable backbone amide protons as well as a fraction of N-terminal, C-
terminal and side chain exchangeable protons. In accordance with previous 
HOX data analysis, percent differences greater than 4.5 % are considered 
significant (45, 67-69),3 - 4.5 % is moderate and < 3 % is modest. 
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Results 
1 mM Divalent Metals and FXIII - HDX-MS 
Human plasma contains 1-2 mM calcium, therefore the solvent 
accessibility of FXIII zymogen (without metals) was compared to that of FXIII in 
the presence of 1 mM Ca2+, Mg2+, 8a2+ or Cu2+. All studies would thus be carried 
out in the presence of a physiological cation concentration environment. Prior 
knowledge about these divalent cations includes the following derived from 
studies carried out at concentrations from 0.1 to 10mM. Mg2+ is smaller in size 
than Ca2+ and does not promote the conformation-based fluorescence changes 
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Figure 8: The number of deuterons incorporated at 10 min for FXIII under the following conditions 
zymogenic (no metal) FXIII (black), 1 mM Ca2+ (up diagonal) , 1 mM Mg2+ (grey), 1 mM Ba2+ (down 
diagonal) and 1 mM Cu2+ (white). The top of the graph illustrates regions of interest in FXIII. Error bars 
represent the standard deviation of the mean for 3 independent trials . 
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FXllialia activity but does protect against thrombin-catalyzed proteolysis at the 
secondary cleavage site (57, 70). Larger in size than Ca2+, 8a2+ exhibits no 
protection against secondary cleavage and modest ability to support FXllialia 
activity (33, 57). Cu2+ is a transition metal that is closer in size to Ca2+ and exerts 
no protection of the K513-S514 site but can support some FXllialia activity (33, 
57). 
For the current conformational studies on FXIII A2 , Table 1 displays 
changes in deuterium incorporation of FXIII zymogen compared to FXIII-(Ca, Mg, 
Table 1: Changes in Percent Deuteration: FXIII with 1 mM Metal Relative to FXIII 
Zymogena. 
Theo 
Residues Dmax b 1 mM Ca2+ 1 mM Mg2+ 1 mM Ba2+ 1 mM Cu2+ 
1-23 23.3 -19.1c -14.6 -22.9 -20.7 
32-40 8.9 -12.7 -6.6 -10.9 -8.5 
83-99 23.2 -0.4 -5.6 -6.3 -6.5 
88-98 10.9 9.2 7.3 4.6 3.5 
100-111 11.8 -4.1 -3.4 -5.0 -3.6 
214-230 18.8 8.8 n/ad 6.2 2.5 
220-230 12.3 5.6 0.7 4.3 3.1 
240-247 7.5 5.3 2.2 6.3 8.7 
248-264 15.9 2.9 3.3 3.6 4.0 
248-265 18.8 2.1 0.3 1.4 2.8 
300-314 15.8 8.7 0.8 3.0 -7.4 
364-372 8.4 3.5 -1.0 -2.9 -2.3 
407-424 18.8 3.6 4.0 9.7 -2.8 
513-522 9.7 -9.0 -9.7 -11.3 -11.6 
533-550 20.1 0.5 -6.0 -6.4 -6.8 
632-646 14.7 3.2 -2.8 -1.9 -1.1 
a The % change for a particular peptide was calculated by the following equation: % difference - ((0 -
OFXIII)/Omax) x 100 % , where 0 is the amount of deuterium incorporated in FXIII with metal, OFXIII is the 
amount of deuterium incorporated in the zymogenic state (no metal), and Omax is the theoretical maximum 
number of exchangeable protons within the indicated peptide. b The maximum number of exchangeable 
protons within the indicated peptide, assuming 100 % deuteration. This value accounts for all exchangeable 
backbone amide protons and a slight fraction of N-terminal, C-terminal, and side chain exchangeable protons, 
which are dependent on the final percentage of 020 in solution under quench conditions (-4.5 %). A fully 
deuterated peptide would theoretically have acquired this amount of deuterons. C The values in bold represent 
Significant changes in deuteration greater than -4.5 %. d n/a refers to a peptide that was either not observed 
in the peptic digest or was not of sufficient intensity to quantify. 
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Ba and Cu). The total deuterium incorporated for each pepsin-derived peptide is 
displayed in Figure 8. Note that the top of the chart highlights the different FXIII 
regions where the peptides reside. 
Within the ~ sandwich domain, the two main regions of interest are the 
activation peptide (1-37) and the putative Gin substrate recognition site (72-97), 
also known as peptide 4. After 10 minutes of HDX, the activation peptide 
became more protected from solvent relative to its values in the zymogen state of 
FXIII. Such protection was observed for all the metals tested and ranged from -
6.6 % for FXIII-Mg to -22.9 % for FXIII-Ba. The peptide 4 segment (71), is 
represented by the pepsin derived peptides 83-99 and 88-98. For peptide 83-99, 
changes in deuteration ranged from -0.4 % for FXIII-Ca to -6.5 % for FXIII-Cu. By 
contrast, the region 88-98 became more exposed in the presence of all metals 
ranging from 3.5 % for FXIII-Cu to 9.2 % for FXIII-Ca. The different responses 
for 83-99 versus 88-98 suggest that the amide protons from residues 83-87 
and/or 99 may be responsible for the HDX protection observed for 83-99 in the 
presence of divalent metals (Figure 8). Further support for the importance of 
residue 99 comes from the observation that the next FXIII segment 100-111 
exhibits solvent protection in the presence of all the cations tested. 
The catalytic core contains several regions of interest. Peptide 7 (190-
230), another putative glutamine-substrate region (71), displayed increased 
deuterium incorporation for metals when compared to zymogen. FXIII-Ca was 
the most exposed for peptides 214-230 and 220-230 followed by FXIII-Ba, FXIII-
Cu, and finally FXIII-Mg. The dimer interface between the two FXIII-A monomers 
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(residues 240-265) was another region where increases in deuterium 
incorporation for all the metals was observed. Exposure within the dimer 
interface (240-247) for FXIII-(Ca, Mg, Ba and Cu) when compared to zymogen 
was 5.3, 2.2, 6.3, and 8.7 % respectively. As with the peptide 7 region, FXIII-Mg 
exhibited the smallest effect. Interestingly, protection from solvent (-3.4 to -5.0%) 
was observed for the residues 100-111. The C-terminal portion of this segment 
is located at the dimer interface; however, the more N-terminal portion is found in 
a ~-sandwich region. 
The catalytic C314 is found within segment 300-314 and the catalytic 
H373 is found one residue outside 364-372. For the 364-372 segment 
containing the H373, 1 mM Ca2+ showed a moderate 3.5 % increase in HDX 
exposure whereas the other metals all showed a modest protection. By contrast, 
FXIII-Ca displayed considerable exposure (8.7 %) for 300-314 when compared to 
FXIII-(Mg and Ba) with 0.8 % and 3.0 % exposure, respectively. FXIII-Cu was 
the only condition found to be protected in this region (-7.4 %). FXIII-Cu also 
became modestly protected in the region of 407-424 which is N-terminal to the 
FXIII Ca2+ binding site (-2.84 %) and makes contacts across the dimer interface. 
FXIII-(Ca, Mg, and Ba), however, displayed increases in deuterium incorporation 
for this segment. The 407-424 segment may be influenced by a nearby non-
prolyl cis peptide bond that is proposed to playa role in FXIII activation (50). 
The ~-barrels contain the secondary cleavage site (513-514) and the 
lysine recognition site (646-658) (72-73). FXIII-(Ca, Mg, Ba and Cu) all displayed 
protection within 513-522 when compared to zymogen (-9.0 to -11.6%). The 
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nearby FXIII 533-550 is not influenced by 1 mM Ca whereas it is significantly 
solvent protected in FXIII-(Mg, Ba, and Cu) at levels of -6.0 to -6.8%. Peptide 
632-646 is on the N-terminal end of the proposed lysine recognition site and is 
moderately exposed in FXIII-Ca (3.6 %) (73). All other conditions showed little if 
any protection in this region of l3-barrel 2. 
TGase Activity of Nonproteolytically Activated FXIII 
FXIII was 
nonproteolytically 
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Figure 9: TGase activity of nonproteolytically activated FXIII. Samples were 
incubated at 37 °C for 10 minutes then added to the assay components. At 2 
minutes (12 min total total) the K9 substrate was added to the assay and the 
oxidation of NADH is depicted as a function of time. The experimental 
groups are as follows: 50 mM Cu2+ with 2 mM Ca2+ (0,0 IJM/min), 50 mM 
Ba2+ with 2 mM Ca2+ (1.98 IJM/min), 50 mM Mg2+ with 2 mM Ca2+ (9.5 
IJM/min) and 50 mM Ca2+ (10,7IJM/min). 
Berichrom assay (64). When incubated in the presence of several different 
divalent metals including 50 mM Ca2+, Mg2+, Ba2+ or Cu2+, only Ca2+ displayed 
activity (data not shown). After changing the activation conditions to include 2 
mM Ca2+ with 50 mM Mg2+, Ba2+ or Cu2+, minor activity was observed in Mg2+ 
and Ba2+ but not Cu2+ (Figure 9). Factor XIII activity was then monitored using a 
series of other nonproteolytic techniques. FXlllaca was compared to FXIII 
activated in the presence of 500 mM EDA2+ (FXlllaEDA) with 2 mM Ca2+, 500 mM 
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Na+ with 2 mM Ca2+ (FXlllaNa) and 500 mM TMAC+ with 2 mM Ca2+ (FXllla™Ac). 
Using the slope (IJM NADH consumed / min) as an indicator of activity, EDA2+, 
Na+ and TMAC+ displayed an increase in FXIII activity of 291 ± 27.7 %, 156.7 ± 
16.3 % and 194.8 ± 5.5 %, respectively when compared to FXlllaca . 
Nonproteo/ytical/y activated FXllla - HDX-MS 
The conformational dynamics of nonproteolytically activated FXIII were 
also probed using HDX-MS. Due to peak suppression in the MALDI, it was not 
possible to quantify the deuterium incorporated into FXlllaEDA and FXllla TMAC. 
Table 2 thus displays changes in deuterium incorporation of FXIII zymogen 
compared to FXIII in 2 mM Ca2+, FXlllaca and FXlllaNa. The total deuterium 
incorporated in each peptide is displayed in Figure 10. 
Table 2: Changes in Percent Oeuteration: Nonproteolytically Activated FXIII 
Relative to FXIII Zymogena. 
50 mM Na+ 
Theo with 2 mM 
Peptide Dmaxb 2 mM Ca2+ 50 mM Ca2+ Ca2+ 
1-23 23.3 -1S.3c -8.3 n/a 
32-40 8.9 -12.1 -12.7 -12.7 
88-98 10.9 -0.9 -1.9 -1.3 
100-111 11.8 -4.5 -S.2 -5.9 
220-230 12.3 9.3 13.2 17.1 
240-247 7.5 7.2 18.2 19.8 
248-264 15.9 1.4 n/ad 2.5 
248-265 18.8 4.7 2.2 4.5 
300-314 15.8 7.1 7.7 11.7 
407-424 18.8 0.2 -0.1 -0.8 
513-522 9.7 0.0 1.7 1.9 
533-550 20.1 2.6 1S.8 n/a 
a The % change for a particular peptide was calculated by the following equation: % difference = «0 
- OFXIII)lDmax) x 100 % , where 0 is the amount of deuterium incorporated in FXIII with metal, OFXIII is 
the amount of deuterium incorporated in the zymogenic state (no metal), and Omax is the theoretical 
maximum number of exchangeable protons within the indicated peptide. b The maximum number of 
exchangeable protons within the indicated peptide, assuming 100 % deuteration. This value 
accounts for all exchangeable backbone amide protons and a slight fraction of N-terminal, C-
terminal, and side chain exchangeable protons, which are dependent on the final percentage of 020 
in solution under quench conditions (-4.5 %). A fully deuterated peptide would theoretically have 
acquired this amount of deuterons. C The values in bold represent significant changes in deuteration 
greater than -4.5 %. d n/a refers to a peptide that was either not observed in the peptic digest or was 
not of sufficient intensity to quantify. 
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To ensure activity was achieved during HOX, the same activation 
conditions used to confirm nonproteolytic activity were utilized for HOX analysis, 
except 0 20 was substituted for H20. The extent of deuterium incorporation may 
vary relative to previous work since this HOX project was conducted at 3rC. 
When activated in the presence of 50 mM Ca2+ or in 500 mM Na + with 2 mM 
Ca2+, the 13 sandwich activation peptide of FXlllaca and FXlllaNa was more 
protected than in FXIII zymogen. This effect was seen in the -12.7 % change 
found for residues 32-40 in both FXlllaca and FXlllaNa. Residues 100-111 fall 
within 4 A of the dimer interface and they too displayed protection of -6.2 % and -
5.9 % for FXlllaca and FXlllaNa , respectively when compared to zymogen. 
Peptide 7 within the catalytic core became notably exposed when 
nonproteolytically activated leading to a 13.2 % increase in deuterium 
incorporation for FXlllaca and a 17.1 % increase for FXlllaNa at residues 220-230. 
The FXIII dimer interface (240-247) within the catalytic core experienced an 18.2 
% (FXlllaca) and 19.8 % (FXlllaNa) increase in solvent accessibility when 
activated. Increased accessibility was also evident within the catalytic cysteine 
containing segment (300-314). This region changed 7.7 % and 11.7 % for 
FXlllaca and FXlllaNa respectively when compared to zymogen (Table 2). These 
various changes in solvent exposure were all greater than what could be 
observed under a more physiological 1-2 mM Ca2+ concentration. Such results 
suggest that these two FXIII regions (peptide 7 and dimer interface) become 
more solvent accessible as the cation concentration is increased (Figure 5). In a 
Na+-containing environment, low mM calcium is required for activation. 
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Events occurring within the 13 barrels are also important to consider. 
Unlike the studies done in the presence of 1 mM Ca2+, no substantial changes in 
solvent exposure were observed for ~-barrel 1 residues 513-522 under the 
nonproteolytic activation conditions at 37 DC. By contrast, accessibility to solvent 
increased steadily from 2 to 50 mM Ca2+ for the neighboring segment 533-550 
(2.6 to 16.8%). Within ~-barrel 2, peptide 632-646 is located N-terminal to the 
lysine recognition region (646-658) and exhibited an increased deuterium 
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Figure 10: The number of deuterons incorporated after 10 min at 37°C for nonproteolytically activated 
FXIII. Deuterium exchange was monitored under the following conditions zymogenic (no metal) FXIII 
(black) , 2 mM Ca2+ (up diagonal), FXlllaca 50 mM Ca2+ (grey) , FXlllaNa 500 mM Na+ with 2 mM Ca2+ 
(whites) . The top of the graph illustrates regions of interest in FXIII. Error bars represent the standard 
deviation of the mean for 3 independent trials . 
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Discussion 
Calcium plays a vital role in the activation and regulation of cellular (A2) 
and plasma (A2B2) FXIII (33, 57-58, 74). HDX provides an effective solution-
based approach for dissecting out how Ca2+ and other divalent and monovalent 
species (Mg2+, Ba2+, Cu2+, Na+, EDA2+, TMAC+) participate in the conformational 
dynamics of this transglutaminase. 
Impact on Ca2+ binding site and surrounding regions 
The FXIII ion binding helix (485-501) is located within 10 A of ~-barreI1 
and also makes contact with the other FXIII-A monomer across the dimer 
interface (42, 55, 75). See golden helix in Figure 11. The primary calcium 
binding site involves FXIII residues Asn436, Asp438, Ala457, Glu485 and Glu490 
(Figure 11 pink sticks) and site-directed mutagenesis studies have demonstrated 
that when the glutamate residues are removed, FXIII sensitivity to Ca2+ 
decreases (27, 55-56). According to Lewis et al., when Ca2+ concentrations are 
< 2.5 mM, there is one Ca2+ bound per FXIII-A, but there are up to 8 low affinity 
sites when the concentration is raised above that threshold (70). The presence 
of strong and weak Ca2+ binding sites has also been confirmed by 43Ca NMR 
studies (76). Our studies to determine the conformational dynamics of FXIII A2 in 
1 mM metal were performed to mimic physiological Ca2+ concentrations and to 
monitor events where a single Ca2+ should target the higher affinity metal site on 
FXIII. The other divalent metals were examined under these same 1 mM 
concentration values. 
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Although sequence coverage was not observed for the FXIII calcium 
binding site, 40 % of the enzyme including a segment containing (513-514), a 
secondary cleavage site that is protected from hydrolysis in the presence of 
calcium was observed (57). This site of proteolytic degradation (red sticks) is 
located just 12 residues down from the ion binding helix (485-510). See Figure 
11. All metals tested at 1 mM concentration (Ca2+, Mg2+, Ba2+, and Cu2+) 
demonstrated solvent protection around peptide 513-522. This finding was 
surprising considering that Mary et al. reported Ba2+ and Cu2+ provided no 
protection against 2° cleavage (57). 
Unlike the 513-522 region, 1 mM Ca2+ did not show any deuterium 
protection for the nearby 533-550 segment (Figure 11 purple) which is part of an 
anti-parallel p-sheet that runs adjacent to 513-522. By contrast, the other divalent 
metals Mg2+, Ba2+ and Cu2+ all showed substantial protection within 533-550 
when compared to FXIII in 1 mM Ca2+. The HDX results suggest that Ba2+ and 
Cu2+ exert a greater influence on 533-550 with additional effects on 513-522; 
however, these events are not sufficient to protect FXIII from proteolysis. 1 mM 
Ca2+ may exert a more direct influence on the secondary cleavage site 513-514. 
The ability of 1 mM Mg2+, Ba2+ and Cu2+ to influence FXIII dynamics brings 
up the question of whether such divalent metals could support nonproteolytically-
derived TGase activity as already observed with Ca2+. Solutions containing 50 
mM Mg2+ or Ba2+, however, all required the added presence of 2 mM Ca2+ to 
produce FXIII activity following 10 minutes of nonproteolytic activation at 3rC. 
Furthermore, their levels of enzymatic activity were all less than those for 50 mM 
35 
Ca2. By contrast, Factor XIII in 50 mM Cu2+, even in the presence of 2 mM Ca2+, 
was not able to yield TGase activity. From these studies, it is evident that a 
series of divalent metals can support FXIII activation and TGase activity but low 




Figure 11: Illustration of the regions within the catalytic core and the Ca2+ binding site mentioned in the 
conformational dynamics of FXIII A2 (1 F13). FXIII A2 (inset) has each domain labeled: l3-sandwich (blue) , 
catalytic core (red), l3-barrel 1 (green) and l3-barrel 2 (yellow) with the box representing the region of interest. 
The Ca2+ binding site (pink) and the ion binding helix (gold) are connected to the secondary cleavage site 
513-514 (red sticks) within peptide 513 to 522 (dark blue) through the (green) connector. The influence on 
the catalytic triad (light blue sticks) is seen through the (green l3-sheet) connector between peptide 533-550 
(purple) and Tyr560 (yellow) . FXIII monomer A is (black) and monomer B is (silver) . Image constructed 
utilizing VMD (51). 
As mentioned previously, the FXIII segment 513-522 exhibits a decrease 
in deuteration in the presence of 1 mM Ca2+ and no change is observed for the 
segment 533-550. These results led to an interest in monitoring FXIII 
conformational dynamics after incubation in an environment of 2-50 mM Ca2+ at 
physiological 3rC. Curiously, the protective effect on 513-522 was lost and 
replaced with a steady increase in the exposure of 533-550. In the X-ray 
crystals, the FXIII active site is occluded by Y560 (Figure 11 yellow sticks) which 
resides only 10 residues from 533-550. Steady increases in Ca2+ concentration 
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might promote movement of Y560 thus assisting C314 exposure to substrate. X-
ray crystallographers have previously predicted that ~-barrel 1 must move 
somewhat away from the catalytic core during the activation process (42) . 
Moreover, Y560 will need to be displaced from its H-bonding interaction with 
catalytic C314. Since the active site reg ion becomes more exposed at higher 
Ca2+ levels, it is possible the FXIII 533-550 segment contributes a line of 
communication to this process. In further support of this proposal , Andersen and 
Faber observed their own increases in HDX based solvent exposure for FXIII 
peptides spanning 533-551 , 556-559, and 560-573 upon formation of FXlliCa 
(46) . 
Metal Influence on Dimer Interface 
The ion binding helix has direct interactions with the FXIII A2 dimer 
interface. According to surface calculations, the dimer interface covers 2280 A2 
and there is a 10.3 - 14.4 kcal/mol decrease in FXIII-A free energy upon 
Figure 12: An illustration of all peptic peptides which yield sequence coverage along the dimer interface 
(1 00-1 11, 240-265 and 407-424) are labeled (red) for FXIII monomer A and (gold) for monomer B. Image 
constructed utilizing VMD (51) . 
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dimerization (36, 42). Key interactions between the two FXIII-A monomers are 
found between K113-D367', K257-E401' and R260-D404'. See Figure 12 for 
HDX coverage of the dimer interface. The exposure reported previously (43) 
around the dimer interface for peptide 240-247 is also seen in the presence of 
just 1 mM Ca2+. This dimer interface exposure is further supported by increases 
in deuterium incorporation now recorded for 248-264 and 248-265. Solvent 
exposure around the dimer interface is also observed with 1 mM 8a2+ and Cu2+ 
but to a lesser extent by Mg2+. Although 100-111 is also positioned along the 
dimer interface, this peptide segment exhibits protection from deuterium 
exchange. Only the most C-terminal portion is actually along the dimer interface. 
The remaining segment is directed into the p-sandwich region which exhibits 
protection. These results indicate that a series of different divalent ions can 
disturb interactions between the two FXIII-A monomers. Such events occur even 
at Ca2+ levels insufficient to support FXIII activation. 
Further increases in solvent accessibility along the A2 dimer interface (aa 
240-264) could be observed when the FXIII was nonproteolytically activated at 
3rC with 50 mM Ca2+ (FXlllca) or 500mM Na+/ 2mM Ca2+ (FXIIINa). Under 
different HDX conditions, this same region was seen to increase in accessibility 
when activated by lIa as well as when inhibited by IAA and Kg DON (43). The 
disruption along the dimer interface due to increasing levels of cations may also 
be due to the noncanonical Ca2+ binding site reported for TG2 (S1 226-233) 
which is homologous to 264-271 found on the dimer interface of FXIII (77). 
Interestingly, a Yb binding site (Figure 13 green) has been shown by X-ray 
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crystallography to be in the vicinity of FXIII residue 271 (42). Vee et al. proposed 
that an opening in the FXIII A2 dimer interface may allow for the lysine acyl-
acceptor to access the catalytic core (27). 
Catalytic C314 Region and Substrate Recognition 
The exposure of the catalytic C314 is imperative for FXIII activity. Of the 
metals tested at 1 mM, Ca2+ promoted the largest increase in solvent 
accessibility for the FXIII 300-314 region. See orange peptide in Figure 13. 8a2+ 
exerted a mild increase on this region and Mg2+ remained essentially the same 
as zymogen. Cu2+ was unique in that it demonstrated substantial protection of 
300-314 when compared to zymogen. These HDX results substantiate the lack 
of TGase activity observed in the presence of Cu2+ and suggest that the 
observed solvent protection might thwart substrate interactions around the 
catalytic cysteine. 
Figure 13: Illustration of the substrate recognition regions and dimer interface mentioned in the 
conformational dynamics of FXIII A2 (1 F13) . FXIII A2 (inset) has each domain labeled: l3-sandwich (blue) , 
catalytic core (red) , l3-barrel 1 (green) and l3-barrel 2 (yellow) with the box representing the region of 
interest. The sequence coverage around the peptide 7 (cyan) the catalytic triad (red) and their close 
proximity to the dimer interface and the Yb binding site 270-272 (green) . Pepsin peptide 300-314 is 
(orange) and 407-424 is (magenta). FXIII monomer A is (black) and monomer B is (silver) . Image 
constructed utilizing VMD (51). 
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Additional HDX results at physiological temperature revealed that 2 mM 
Ca2+ had nearly the same effect on exposure of the 300-314 region as activating 
FXIII with 50 mM Ca2+ (FXlllaca). Such results suggest that low mM Ca2+ 
contribute to initial exposure of C314. Further conformational changes likely 
located within the catalytic core, the dimer interface, and/or ~-barrel 1 must 
provide the vital link to achieve full FXIII activation and thus ability to target 
actions at C314. 
Interestingly, segment 407-424 exhibits increased deuteration at 1 mM 
Ca2+ but loses this solvent exposure when the temperature is raised to 3rC and 
then 2-50 mM Ca2+ is employed. The 407-424 segment may be influenced by a 
nearby non-prolyl cis peptide bond Q425-F426 that is in proximity to the dimer 
interface. Earlier work by our group (60) demonstrated that that FXIII C409 could 
be alkylated with NEM when the enzyme was nonproteolytically activated with 50 
mM Ca2+ and then re-equilibrated back to 1 mM. This ability was, however, lost 
when the exposed FXIII active site was blocked with an inhibitory Q-containing 
peptide (43). Weiss and coworkers proposed that conversion of a FXIII non-
prolyl cis peptide bond to the more energetically favored trans could help drive 
larger scale conformational changes to fully expose the FXIII active site region 
(50). The current increases in Ca2+ concentration and temperature may have 
aided in establishing an environment that helps promote the next alterations in 
FXIII conformation. Such an environment may contain a more solvent protected 
FXIII 407-424 segment. 
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Peptide 4 (72-97) in the ~-sandwich and peptide 7 (190-230) in the 
catalytic core are proposed glutamine substrate recognition regions (71). Peptide 
7 is represented by the cyan peptide in Figure 13. FXIII A2 in 1 mM Ca2+ 
displayed enhanced solvent accessibility relative to zymogen for both 88-98 and 
214-230. This FXIII exposure around the glutamine recognition region also 
appears to be Ca2+ specific as it induces the greatest effect compared to the 
other metals. By contrast, Cu2+ exhibited the smallest amount of exposure and 
thus appears to be least likely to allow for glutamine recognition. Within peptide 
4, there are differences in solvent exposure depending on the metal tested. In 
the peptide segment 83-99, the percent incorporation with 1 mM Ca2+ is 
essentially the same as with zymogen whereas Mg2+, Ba2+, and Cu2+ show 
protection. Within the peptide segment 88-98, Ca2+ promoted more exposure 
than Mg2+ and Cu2+. Another region of interest is the Lysine recognition site 646-
658 in ~-barrel 2 (72). A peptide located N-terminally to this site, 632-646, is only 
exposed in the presence of 1 mM Ca2+, whereas Mg2+, Ba2+ and Cu2+ all display 
protection in this region. 
The proposed glutamine substrate binding site, peptide 7 (190-230), is 
located in close proximity to the Ca2+ binding site and comes within 3 A of a loop 
which connects D438 to E485 and E490 within the Ca2+ binding pocket. For the 
nonproteolytically activated forms FXlllaca and FXlllaNa, the residues 220-230 
exhibited further increases in deuterium incorporation in comparison to the 1-2 
mM Ca2+ conditions. The peptide 7 substrate recognition sequence is another 
example of a FXIII region that undergoes initial conformational changes at 
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physiological Ca2+ levels and then exhibits greater exposure at higher ion 
concentrations. 
Low mM Metals: Activation Peptide 
The activation peptide (1-37) is cleaved by lIa during physiological 
activation . Residues 1-23 became protected in the presence of 1 mM Ca2+ as 
well as 1 mM Mg2+, Ba2+ and Cu2+. The activation peptide was also protected 
after nonproteolytic activation with 50 mM Ca2+ at 3rC, albeit somewhat less 
than 1 mM Ca2+ at room temperature. Both the FXIII 1-23 and 32-40 segments 
exhibited protection in the HDX studies. 
Figure 14: Illustration of the activation peptide and its intimate contact the opposing FXIII-A monomer 
(1F13) . FXIII A2 (inset) has each domain labeled: l3-sandwich (blue), catalytic core (red), l3-barrel1 (green) 
and l3-barrel 2 (yellow) with the box representing the region of interest. Depiction of the N-terminal activation 
peptide of FXIII monomer B (silver surface) labeled according to residue type (green = polar, white = 
nonpolar, red = acidic and blue = basic) and Arg11 and Arg12 are shown as (blue) sticks. The AP crosses 
the dimer interface and Asp373' from FXIII monomer A is hydrogen bonded to Arg11 in close proximity to 
the catalytic triad (yellow) and Tyr560 (orange) . Image constructed utilizing VMD (51). 
It was reported recently that the FXIII AP is free in solution after lIa 
cleavage and available for binding to monoclonal antibod ies specific to FXIII-AP 
(78). Our HDX results suggest that in the presence of Ca2+ the unhydrolyzed AP 
remains tightly associated with FXIII A2. Figure 14 shows how the activation 
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peptide segment straddles across both monomer units and that this segment 
contains a combination of polar and nonpolar residues. Moreover, there are 
acidic and basic side chains that can participate in stabilizing interactions with the 
FXIII surface. Interestingly, R11 (Figure 14 blue sticks) from the activation 
peptide segment is hydrogen bonded to 0373' on the opposite unit of the dimer. 
This R11 - 0373' interaction is also in close proximity to the FXIII catalytic triad 
and the vital Y560. Other hydrogen bonds also seem to anchor the FXIII AP 
above the catalytic core. 
Earlier studies by Lewis et a/ reported that an additional 8 weak metal 
sites could be found on FXIII at higher Ga2+ concentrations. The AP region 
and/or a complementary segment on the p-sandwich domain may accommodate 
some of these divalent ions (70). Further studies will be needed to assess 
whether the AP segment may aid in channeling Gin substrates towards the 
catalytic core. An alternative possibility is that the binding of large physiological 
substrates will later assist in displacing this cleaved portion of FXIII from the 
vicinity of the transglutaminase active site. 
Further Characterizing Nonproteo/ytic Activation 
Polgar et a/. demonstrated that FXIII A2 can be activated albeit slowly by 
150 mM NaGI and 2 mM Ga2+ (40). More efficient activation occurs when NaGI is 
raised to the 500 - 1000mM level. Low calcium, however, is still necessary. In 
the current work, the organic mono and divalent cations, TMAG+ and EOA2+, 
were investigated for the first time. The pH of the TGase activity assay is 7.4 and 
EOA2+ pKa1 is 7.56 and pKa2 is 10.71 ensuring a mostly divalent (60 %) EOA2+ 
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ion. As observed with Na+, TMAC+ and EOA2+ each required some calcium to 
elicit FXIII transglutaminase activity. Curiously, TGase activity for the TMAC+, 
Na+, and EOA2+ conditions (all containing 2 mM Ca2+) were greater than that of 
50 mM Ca2+, our standard nonproteolytic activation method. Such results further 
emphasize the important role of Ca2+. Moreover, the novel use of organic 
cations EOA2+and TMAC+ suggests that activation is not only driven by metal ion 
binding interactions. Unfortunately, ionization issues in the MALOI hindered 
ability to carry out HOX projects with FXlllaEDA and FXllia TMAC. 
Overview of Results: 
In the current project, the FXIII A2 was monitored in the presence of Ca2+, 
Mg2+, Ba2+, Cu2+, Na+, EOA2+, and TMAC+ with concentrations ranging from 1-2 
mM up to 50-500 mM for nonproteolytic activation. Several regions were found 
where physiological Ca2+concentrations initiate the changes needed for activity. 
As expected, 1 mM Ca2+ does lead to solvent protection for the FXIII region 
containing the 513-514 secondary cleavage site. Surprisingly, Ba2+ and Cu2+ 
could protect FXIII 513-522 and 533-550 from solvent even though these two 
divalent cations do not shield against secondary cleavage (57). By contrast, 
increasing concentrations of Ca2+ promoted exposure of 533-550. Such Ca2+ 
induced effects may playa role in exposing the FXIII reactive thiol group by 
helping to disrupt the H-bond between C314 and Y560. When considering other 
cations, Mg2+ and Ba2+ could both promote non proteolytic activation in the 
presence of low mM Ca2+ whereas Cu2+ could not. The presence of Cu2+ seems 
to hinder exposure of the active site C314 as well as the Gin substrate 
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recognition region. Our HDX studies also revealed that 1 mM Ca2+ increased 
deuterium incorporation at the dimer interface, around the lysine recognition 
region (632-646), and at two glutamine substrate recognition regions, peptide 4 
(83-99) and peptide 7 (214-230). These trends continued in nonproteolytically 
activated FXIII. 
There has been much speculation about whether FXIII A2 can adopt an 
open conformation similar to that reported by Pinkas et al. for TG2 (49). 
Conformational changes to activated FXIII A2 can clearly be observed by mass 
spectrometry approaches. The gross increases in solvent accessibility that 
would be expected if the p-barrels had pulled fully away from contacting the 
catalytic core surface, however, are not observed. The fact that FXIII functions 
as a dimer may be a contributing element to the difference in behavior of TG2 
and FXIII-A2. The dynamic nature of the FXIII in solution is also important to 
consider. 
Calcium appears to play an intriguing regulatory role in FXIII (33, 56, 58, 
79). Low mM levels already begin to initiate important conformational changes 
needed to expose the active site and make the enzyme ready to accommodate 
incoming substrates. Often as divalent cation concentration increases, the 
effects are also enhanced. Physiologically, FXIII is poised to respond to transient 
influxes of Ca2+ in the presence of a Na+ containing environment (40, 52-53). 
Platelet FXIII A2 is quite sensitive to such changes in solution environment and 
can be more readily activated nonproteolytically (40, 52-53). The initial 
conformation events that have been observed in the current study help set the 
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stage for the larger conformational changes that are anticipated in the presence 
of a physiological substrate or inhibitor. 
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CHAPTER III 
COMPARING THE SOLVENT ACCESSIBILIT OF FXIII-A2 TO THE OPEN 
AND CLOSED FORM OF TRANSGLUTAMINASE 2. 
Introduction 
Very few structural changes have been observed in FXIII when comparing 
the crystal structures of proteolytically activated and nonproteolytically activated 
FXIII to zymogen. TG2 on the other hand was recently crystallized bound to an 
inhibitory peptide substrate in an 'open' conformation (49, 51). Comparing these 
two enzymes in solution will allow for a much better judgment as to whether the 
A C 
Figure 15: Structure of GOP-Bound and Inhibitor-Bound TG2 and FXIII-A2 Oimer. The N-
terminal ~-sandwich is in blue, catalytic core in green, and the C-terminal ~-barrel 1 and ~­
barrel 2 in yellow and red respectively . A- GOP-bound (closed) TG2 (1 KV3) . B- TG2 inhibited 
(open) with substrate peptide inhibitor Ac-P(OON)LPF-NH2 (2Q3Z) . C- Factor XIII-A2 dimer 
(1 F13) . 
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FXIII-A2 dimer also goes through an 'open' conformation like the TG2 monomer 
when activated. 
Comparing the conformational dynamics of FXIII to that of TG2 offers a 
unique opportunity. Although TG2 is physiologically a monomer, it contains the 
same 4 domains (~-sandwich, catalytic core, ~-barrel 1 and ~-barrel 2) as well as 
the same general shape as a FXIII-A monomer. As with FXIII, TG2 is proposed 
to go through a major conformational change during activation or substrate 
binding, but unlike FXIII, TG2 bound to substrate has now been crystallized in an 
open conformation (Figure 15 (49, 80)). TG2 is activated in the presence of 
millimolar Ca2+ but unlike FXIII it is inhibited by guanine nucleotides. The 
guanidine nucleotide binding site is located between the catalytic core and ~­
barrel 1. When GTP is bound, the active site is blocked by two loops and the 
catalytic cysteine (C277) is H-bonded to Y516 a neighboring tyrosine (81). In the 
absence of Ca2+, the GTPase activity of TG2 utilizes several G protein-coupled 
receptors to mediate intracellular signaling (21, 25). 
The first step in comparing the solvent accessibility of FXIII to that of TG2 
is identifying the peptides generated during TG2 pepsin digestion. Pepsin is a 
non-specific specific enzyme; therefore, it is difficult to predict cleavage products 
but their cleavage pattern is very reproducible when conducted under the same 
conditions (pH, Temp., etc.). Once the peptic peptides were identified and 
sequence coverage determined, HDX was used to determine the conformational 
dynamics of TG2 while unactivated (zymogen), activated in the presence of Ca2+ 
and substrate inhibited. 
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Although Hausch was the first to inhibit transglutaminase activity by 
replacing the substrates reactive glutamine with 6-diazo-5-oxo-L-norlueucine 
(DON), Sabo et al.was the first to utilize DON to monitor the conformational 
dynamics of a transglutaminase with substrate bound (43, 82). DON is an 
electrophilic amino acid which acts as an inhibitor by covalently binding to the 
catalytic cysteine via a thioether linkage (Figure 16). The substrate peptide K9 
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Figure 16: Kg DON Inhibition of FXllla. A. The isosteres glutamine and 6-diazo-5-oxonorleucine. B. The 
proposed mechanism of inhibition proceeds through tetrahedral intermediate formation resulting from 
cysteine attack at the carbonyl group. The methylene carbon then abstracts a proton from the active site 
H373. Finally, a thioether is formed resulting in the release of N2 and irreversible inhibition of FXllla(43, 80). 
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conformational dynamics of FXIII-A2 when activated and bound to inhibitor (43). 
HDX was utilized in the current study to monitor TG2 conformational dynamics 
during activation as a function of calcium concentration and when bound to TG-
DON, a gluten peptide (Ac-P(DON)LPF-NH2) inhibitor substrate. Surprisingly 
there was not a gross increase in deuterium incorporation across TG2. Within 
the catalytic core, several regions, 451-461 and 369-377, became protected 
when activated and inhibited. The regions 259-269 and 475-487 became more 
exposed only when TG2 was in an open conformation bound to inhibitor 
substrate. There are antibodies already available that are specific for the open 
conformation of TG2 and the open conformation is being targeted for 
pharmaceutical design. The knowledge gained in understanding the regions of 
TG2 that become more accessible to solvent when in the open conformation will 
assist in determining whether FXIII-A2 undergoes a similar open conformation 
that has been reported for TG2 (49). 
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Materials and Methods 
Transglutaminase 2 and TG-OON Preparation 
Transglutaminase 2 was purchased from Zed ira (Darmstadt, Germany). 
Lyophilized recombinant human TG2 (1 mg) was reconstituted in 18 MO 
deionized water, then buffer exchanged into 25 mM Tris-base at pH 7.4. The 
concentration of TG2 was determined on a Cary 100 UV/vis spectrophotometer. 
The absorbance was monitored at 280 nm and concentration calculated with the 
TG2 extinction coefficient of 106,020 M-1cm-1. The extinction coefficient was 
determined using Expasy ProtParam tool (http://web.expasy.org/protparam/). 
Aliquots (12 IJI) of 50 IJM TG2 in 25 mM Tris-base were stored at -70°C until 
future use. 
The gluten derived TG2 inhibitory peptide TG-DON (Ac-P(DON)LPF-NH2) 
was purchased from Zedira (Darmstadt, Germany). The lyophilized powder (10 
mg) was solubilized in 1.5 ml DMSO and a sample was sent to AAA Service 
Laboratories (Damascus, OR) for analysis. The TG-DON concentration was 
determined to be 8.5 mM and stored at 4°C. Purity was assessed by HPLC and 
mass spectrometry approaches. 
The a2 antiplasmin (a2AP-Q4N) derived substrate peptide 
CNQENVSPLTLLKLGN15) was synthesized by SynPep Corp (Dublin, CA). The 
a2AP peptide was reconstituted in 18 MO deionized water and the concentration 
(6.8 mM) was confirmed by quantitative amino acid analysis (AAA Service 
Laboratory, Inc., Boring, OR). Purity was assessed by HPLC and mass 
spectrometry approaches. 
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TG2 Transglutaminase Activity Assay 
TG2 activity was determined using a modified version of the Dade-Behring 
Berichrom Assay (62-63). Briefly, this assay utilizes a coupled reaction involving 
both TG2 and glutamate dehydrogenase (GDH). Activated TG2 reacts with the 
acyl-donor a2AP-Q4N releasing NH3 and the transglutaminase reaction 
concludes when the primary amine acyl-acceptor, glycine ethyl ester, forms an 
isopeptide bond with the a2AP-Q4N peptide. This transglutaminase activity is 
monitored via the conversion of a-ketoglutarate and NH3 into glutamate in the 
presence of reducing equivalents of NADH. The oxidation of NADH results in 
decreased absorbance at 340 nm. 
TG2 aliquots were diluted to 1 0 ~M in 25 mM Tris. For each assay, TG2 
(200 nM) was in solution with activator reagent (163 ~I), detector reagent (250 ~I) 
and CaCb (10 mM) (64). For monitoring TG-DON inhibition, TG-DON was also 
added (0.01 - 1000 nM). The assay contents were placed in a Cary 100 UV/vis 
spectrophotometer and incubated for 8 min at 37°C for before the a2AP-Q4N 
substrate peptide was added. Oxidation of NADH was monitored for 30 minutes 
at 340 nm and the activity was determined by the steepest part of the slope. The 
slope represents the velocity of the reaction as ~abs/min. TG-DON is solubilized 
in DMSO, therefore a control experiment was run to confirm that 2 % DMSO did 
not affect activity of TG2 (data not shown). In previous studies, Factor XIII 
activity also was not affected with 2 % DMSO (43). 
HDX Experimentation 
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Hydrogen deuterium exchange was utilized to elucidate regions of TG2 
that become more accessible to solvent when activated and inhibited. A 12 IJI 
aliquot of 50 IJM TG2 was allowed to come to room temperature. Due to TG-
DON being solubilized in DMSO, all samples were adjusted to the same 
concentration of DMSO. TG2 zymogen was prepared by adding 1.0 IJI dH20 and 
0.3 IJI DMSO to a 12 IJI aliquot of 50 IJM TG2 for an assay concentration of 45 IJM 
TG-2 in 2 % DMSO. For Ca2+ activated TG2, 1.0 IJI 26.6 mM CaCb and 0.3 IJI 
DMSO were added to a 12 IJI aliquot of 50 IJM TG2 for an assay concentration of 
45 IJM TG2 in 2 mM Ca2+ and 2% DMSO. Lastly, the activated and inhibited TG2 
was prepared by adding 1.0 IJI 26.6 mM CaCb and 0.3 IJI 8.5 mM TG-DON to a 
12 IJI aliquot of 50 IJM TG2 for an assay concentration of 45 IJM TG2 in 2 mM 
Ca2+, 191 IJM TG-DON and 2% DMSO. Each sample was incubated at 37°C for 
10 min. then evaporated to dryness in a CentriVap Centrifugal Vacuum 
Concentrator (Labconco, Kansas City, MO) and placed at -70°C until use. 
The following HDX protocol was adapted from methodology established in 
the Komives laboratory (65-66). The dry FXIII aliquot was allowed to reach room 
temp before 12 IJI of 99.996% 0 20 (Cambridge Isotope Laboratories) was added 
yielding a final working concentration of 50 IJM TG2, 2.2 IJM Ca2+ and 213 IJM 
TG-DON. The samples were incubated at room temperature for 10 minutes 
before the HDX was quenched by adding 120 IJI of chilled 0.1% TFA at pH 2.5. 
The quenched reaction was then immediately transferred to a tube containing 
activated pepsin bound to 6% agarose (Thermo Scientific, Rockford, IL). Pepsin 
digestion occurred for 10 min on ice. Following digestion, the reaction mix was 
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centrifuged for 30 sec to separate the TG2 digest from the pepsin beads. Three 
8.2 IJI aliquots were immediately frozen in liquid N2 and each reaction condition 
was performed three times. 
In addition to investigating TG2 while inhibited with TG-DON, TG2 was 
also activated under different concentrations of Ca2+ (2, 5, and 10 mM) in the 
absence of DMSO, and it was determined that DMSO did not playa role in the 
conformational changes reported (data not shown). 
HDX Analysis 
A FXIII(a) HDX aliquot was thawed at room temperature and immediately 
mixed with an equal volume of 10 mg/ml a-cyano-hydroxycinnamic acid matrix 
(a-CHCA) (Aldrich) in 1:1:1 ethanol/CH3CN/0.1%TFA at pH 2.2, and 0.51J1 was 
spotted on a chilled MALDI plate. The sample spot was then quickly dried by 
placing the MALDI plate into a SpeedVac. The plate was then immediately 
inserted into the MALDI-TOF-MS (Voyager DE-Pro, Applied Biosystems). 
Spectra were collected in reflector mode with 256 shots/spectrum. All peptides in 
the peptic digest were identified using GPS ExplorerTM after MS/MS analysis on 
an Applied Biosystems 4700 in the laboratory of M. Merchant at University of 
Louisville. After digestion by pepsin, the TG2 peptides identified represent 37 % 
coverage (Figure 17). Peptide identification was confirmed through observing the 
same peptide sequence in multiple independent digests, with an ion score 
preferably above 20 (peptic peptides Appendix D). These peptides focus on key 
TG2 regions found within the ~-sandwich, the catalytic core, and the ~-barrels. 







































Figure 17: TG2 peptides observed by MALDI-TOF-MS after 10 minute pepsin digestion. The magenta 
area represent peptides observed for TG2 (37 % coverage) . 
improve sequence coverage. All the MALDI spectra derived from pepsin digests 
were analyzed using Data Explorer version 4.8(Applied Biosystems) and 
calibrated using two singly protonated reference peptides; monoisotopic mass 
901.44 Da (residues 369-377) and 2042.18 Da + 11 deuterons at mass 2053.29 
Da (residues 668-686). 
Deuterium incorporation for each isotopic cluster was quantified as 
described by Sabo et al. (67) . To determine the change in deuteration for TG2 
under different conditions the percent deuteration for each peptide was 
calculated using equation 1 (page 23). In accordance with previous HDX data 
analysis, percent differences greater than 4.5 % are considered significant (45, 
67-69), 3-4.5 % is moderate and < 3 % is modest. 
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Results 
TG2 Activity and Inhibition with TG-OON 
The kinetics of 02AP as FXIII-A substrate are well established (83). It has 
also been demonstrated through a Q2N mutation that FXIII will not utilize the Gin 
in position 4 on the 02AP peptide (83). To determine if TG2 also recognizes only 
the Gin in position 2, TG2 activity was monitored with 02AP-Q2N as substrate. 
Like FXIII, TG2 was not catalytically active in the presence of 02AP-Q2N (data 
not shown). The activity of TG2 was confirmed using 02AP-Q4N as substrate. 
Following an 8 minute incubation in the presence of 10 mM Ca2+ at 37°C the 
substrate peptide 02AP-Q4N was added to the cuvette. The inhibitory action of 
TG-OON on TG2 activity was determined by adding TG-OON to the cuvette 
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Figure 18: A plot of % inhibition vs the log of TG-DON concentration. Seven separate trials 
were performed at varying inhibitor concentrations:TG2 in the absence ofTG-DON; 15 nM TG-
DON; 30 nM TG-DON; 50 nM TG-DON; 90 nM K9 DON; 180 nM K9 DON; and 1000 nM K9 
DON. The assay components , TG2, and the indicated amount of TG-DON were incubated for 8 
min at 37 ·C, at which point the substrate o2AP-Q4N was introduced to the assay. All points on 
the curve are marked with red squares and the linear portion used for determining IC50 = 55 nM 
is blue diamonds inside red squares. 
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concentration during activation was 200 nM and TG-DON was monitored over a 
concentration range of 0 - 1000 nM. By plotting the % TGase inhibition versus 
log TG-DON concentration, a sigmoidal dose response curve is observed (Figure 
18). With a TG2 concentration of 200 nM, the IC50 was calculated to be 55 nM 
TG-DON. 
MALDI-TOF-TOF for TG2 Pepsin Peptide Identificaiton 
The first step in comparing the solvent accessibility of FXIII to that of TG2 
was identifying the peptic peptides for TG2. Pepsin is a non-specific specific 
protease; therefore, it is difficult to predict cleavage products but the cleavage 
pattern is very reproducible when conducted under the same conditions (pH, 
Temperature, etc.). Previously in our lab, the peptic peptides of FXIII were 
determined on an Applied Biosystems DE-PRO using Post-Source Decay (PSD) 
(45). MALDI-TOF-TOF MS allows for MS/MS capabilities. An Applied 
Biosystems 4700 was used for acquiring the MS and MS/MS spectra of TG2 
digest products. The mass list was subsequently uploaded into GPS ExplorerTM 
software available through Applied Biosystems. Using GPS ExplorerTM to search 
the MASCOTTM database 16 peptides were identified representing 37 % of TG2 
(Figure 17 in Material and Methods). 
HDX Analysis of TG2 
Once TG-DON binding and inhibition were confirmed HDX was utilized to 
monitor the conformational dynamics of TG2 during activation and in the open-
inhibited conformation. TG2 has been crystallized in an open conformation 
leading to the hypothesis that a gross increase in solvent accessibility would be 
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Table 3: Changes in Percent Deuterationa : Active TG2 (2 mM Ca2+) and Inhibited TG2 (2 
mM Ca2+ with TG-DON) relative to TG2 zymogen a. 
Residues Theo. Dmax b 2mM Ca2+ 2mM Ca2+ TG-DON 
j3-Sandwich 13-26 15.8 -0.3 -0.4 
27-40 15.2 -0.7 -0.6 
32-40 9.4 -0.8 -0.4 
Cat. Core 155-161 8.2 -0.4 -0.7 
238-254 18.0 -0.4 0.2 
260-270 13.0 1.1 4.8 
316-330 17.0 0.0 -0.2 
342-354 12.5 3.3 3.6 
370-378 8.0 -4.2 -4.0 
452-462 12.7 -22.6 -23.4 
453-462 11.6 -23.2 -23.7 
j3-Barrel 1 476-488 14.9 0.2 5.3 
503-509 8.0 0.4 -0.1 
548-555 9.4 2.0 2.3 
561-569 10.2 0.5 1.1 
@-Barrel 2 669-687 20.3 6.0 8.2 
a The % change for a particular peptide was calculated by the following equation: % difference = «D -
DFXllI)/Dmax) x 100 % , where 0 is the amount of deuterium incorporated in FXIII with metal, DFXIII is the 
amount of deuterium incorporated in the zymogenic state (no metal), and Dmax is the theoretical 
maximum number of exchangeable protons within the indicated peptide. b The maximum number of 
exchangeable protons within the indicated peptide, assuming 100 % deuteration. This value accounts for 
all exchangeable backbone amide protons and a slight fraction of N-terminal, C-terminal, and side chain 
exchangeable protons, which are dependent on the final percentage of D20 in solution under quench 
conditions (-4.5 %). A fully deuterated peptide would theoretically have acquired this amount of 
deuterons. C The values in bold represent significant changes in deuteration greater than -4.5 % 
observed by HDX around the catalytic core and ~-barrel interface. HDX allows 
for monitoring TG2 conformational changes in solution, eliminating any possible 
artifacts of the crystallization process. There were four peptides monitored within 
the N-terminal ~-sandwich region, none of which displayed any significant 
changes in solvent accessibility. The catalytic core was better represented and 
several peptides displayed not only increases in solvent accessibility, but also 
protection (Table 3 and Figure 19). 
There were 8 peptides analyzed representing 41 % of the TG2 catalytic 
core (139 - 471). The majority of the catalytic core did not show any large 
changes in solvent accessibility. Starting at the N-terminal end of the catalytic 
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core, peptide 260 - 270 is the first to show a significant change in deuteration. 
When compared to zymogen, TG2 activated with 2 mM Ca2+ only displayed a 1.1 
% increase in solvent accessibility whereas the TG-OON inhibited form increased 
4.8 %. Continuing toward the C-terminus, the next notable region was 342 - 354, 
where both the Ca2+ activated and the TG-OON inhibited conformations had a 
moderate increase in solvent accessibility, 3.3 and 3.6 % respectively. The next 
few regions all experienced protection. The first of which is 370 - 378 which 
experienced a -4.2 and -4.0 % protection for Ca2+ activated and TG-OON 
inhibited respectively. There were two peptides spanning from 452 - 462 and 
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Figure 19: The number of deuterons incorporated at 10 min for TG2 under the following 
conditions zymogenic (no metal) TG2 (Blue) , 2 mM Ca2+ (Red) , 2 mM Ca2+ with TG-DON 
(Green) . Error bars represent the standard deviation of the mean for 3 independent trials . 
when activated or inhibited. 
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Lastly there are the two ~-barrels (~-barreI1 472 - 584 and ~-barrel 2 585 
- 686). The 4 peptides that were analyzed in ~-barrel 1 represented 65 % of the 
113 amino acids. Only one peptide, 476 - 488 had a significant change in 
solvent accessibility. Like the 260 - 270 region, there was not any notable 
change in solvent accessibility when activated with 2 mM Ca2+, but there was an 
increase was observed when inhibited with TG-DON. When inhibited, there was 
a 5.3 % increase in dueteration, whereas Ca2+ activated TG2 only saw a 0.2% 
increase. There was only one peptide (669 - 687) representing 19 % of ~-barrel 
2 available for analysis. Peptide 669 - 687 also represented the 19 C-terminal 
amino acids of TG2. This region saw increases in solvent availability in both the 
Ca2+ activated and TG-DON inhibited TG2. The Ca2+ activated increased 6.0 % 
and the TG-DON inhibited increased 8.2 % when compared to zymogen. 
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Discussion 
Lorand and Graham coined transglutaminase 2 "the bete noir" of the 
transglutaminase family because it was the first of the TGase family discovered 
and its physiological role remains elusive (84). Progress in understanding the 
physiological role of TG2 in apoptosis, cell-matrix interactions and human 
diseases like Central Nervous System (CNS) neurodegenerative diseases, celiac 
disease and cancer has been nicely reviewed (84-86). Understanding the 
function and physiological role of TG2 has also been assisted with a greater 
understanding of its conformational dynamics (49, 87-89). 
Two recent studies have utilized mass spectrometry to monitor the 
conformational dynamics of TG2 (87, 90). Greenberg, et al. monitored TG2 
activity after lysine modification and determined that acetylation of Lys 444,468 
and 663 were essential for inhibition (87). The other study identified a redox-
sensitive cysteine triad (Cys 230, 370 and 371) which need to be fully reduced 
for TGase activity (90). Pinkas et al. has crystallized TG2 trapped in an open 
conformation (49). In the current work, the conformational dynamics of TG2 
were monitored in solution, for the first time, through the utilization of HOX 
coupled with MALOI-TOF-MS. 
TG2HDX 
Crystallography has been utilized to investigate the structure of TG2 both 
in the inhibited (open) and GOP-bound (closed) conformations (49, 91). It was 
apparent that within the ~-sandwich domain there was very little structural 
variability (Figure 20). This lack of conformational dynamics was supported by 
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HDX where there were no regions 
within the l3-sandwich that 
exhibited significant changes in 
solvent accessibility. 
Catalytic Core 
The catalytic core proved to 
be more flexible during activation 
and inhibition . In addition to the 
catalytic triad (C277, H335 and 
D358), it also contains the putative 
Figure 20: Overlay comparison of the TG2 13-
Sandwich domain in the open and closed 
conformations. The green represents GDP-bound TG2 
in the closed conformation and the grey is the TG-DON 
inhibited form of TG2. The overlay was performed 
using the MultiSeq tool in VMD(51) . 
Ca2+ binding sites, the redox-sensitive cysteine triad (C230, 370 and 371) and 
two of the three Iysines (448 and 468) that are essential for inhibition after 
acetylation (77, 87, 90). The exposure experienced from 260 - 270 falls N-
terminally of the catalytic C277. During Ca2+ activation the 260 - 270 region 
experienced a modest (1.1 %) increase in exposure whereas when bound to TG-
DON, there was a 4.8 % increase in exposure. This region is represented by the 
magenta helix (Figure 21) and is separated from C277 by a short l3-strand. The 
260 - 270 helix does not change orientation in the GDP-bound versus TG-DON 
inhibited crystal structures; therefore, the differences observed in deuterium 
incorporation for activated versus TG-DON inhibited TG2 is due to the dislocation 
of the l3-barrels. The residues of 260 - 270 are < 10 A from residues 631-635 of 
l3-barrel2 in the closed conformation . The movement of the two l3-barrel 
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Figure 21: Overlay comparison of TG2 in the open and closed conformations. (A) The green 
represents GOP-bound TG2 in the closed conformation and the grey is the TG-OON inhibited form of 
TG2. Regions of interest are labeled according to protection or exposure to solvent after activation and 
inhibition. Peptides 452-462 and 370-378 (Blue) experienced solvent protection. Peptide 342-354 (pink) 
experienced moderate exposure. Peptides 260-270 and 476-488 (magenta) experienced exposure only 
after inhibition. Peptide 669-687 (red) experienced exposure. (B) GOP-bound TG2 in the closed 
conformation with the same labeling as (A). (C) Inhibited TG2 in the open conformation with the same 
labeling as (A). 
In addition to C277, the catalytic triad also consists of H335 and 0358. 
Peptide 342 - 354 falls between these two residues and 370 - 378 falls 12 
residues C-terminal of 0358. Residues 342 - 354 experienced moderate 
exposure when activated and when inhibited (Figure 21 and Figure 22 pink) . 
This peptide's conformation did not change in the GOP-bound structure when 
compared to the TG-OON inhibited crystal structure. These observations 
indicate that 342 - 354 may become more exposed if the solvent accessibility of 
GOP-bound TG2 was compared to zymogen . The similar structure of 342 - 354 
in GOP-bound and TG-OON inhibited TG2 could be due to the importance of 
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maintaining structural integrity between two of the three catalytic residues. 
Unlike 342 - 354 which became more exposed and displayed a similar 
conformation in the two TG2 crystal structures, 370 - 378 experienced moderate 
protection and a conformational 
change when inhibited. A 
closer look at this region 
demonstrated the intimate 
contact between 370 - 378 and 
the catalytic 0358. In Figure 
22, 370 - 378 (ball and stick, 
red = closed and blue = open) , 
the region observed in HOX 
was viewed with an extension, 





Figure 22: Illustration of the intimate connection between 
the catalytic triad and peptides 342-354 and 370-378. The 
catalytic triad (C277, H335 and 0358) are green ball and 
stick. Peptide 342-354 (pink) is connected to 370-378 (ball 
and stick) via a linker containg 0358. Peptide 342-354 and 
the linker are labeled according to conformation (red = 
closed and blue = open). 
contains 0358. The beta-hairpin motif on the N-terminus of 370 - 378 in the 
GOP-bound TG2 lost its character and became random coil in the TG-OON 
inhibited TG2 crystal structure. Ouring HOX, the solvent exposure of 370 - 378 
decreases 4.2 and 4.0 % for Ca2+ activated and TG-OON inhibited TG2 
respectively when compared to zymogen. In the inhibited form of TG2 the N-
terminus of 370 - 378 underwent a conformational change and lay closer to the 
surface thus supporting the protection observed by HOX (Figure 22). 
There is a disulfide bond reported between C370 and C371 in the open 
conformation of TG2 (49, 90) . Stamnaes et al. monitored TG2 under different 
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oxidizing (GSH/GSSG) conditions and determined that the vicinal C370 - C371 
disulfide was prevalent in the open and oxid ized form (90). The solvent 
protection and observed conformational change at the N-terminus of 370 - 378 
help to substantiate the evidence of vicinal disulfide formation in the open 
conformation. 
The Ca2+ binding site on TG2 has yet to be observed in crystal structures 
and has only been identified through modeling and mutations of noncanonical 
Ca2+ binding regions (77, 88) . One such proposed Ca2+ binding site (S2, 
residues 445 - 455) was identified through sequence homology with the FXIII-A 
Ca2+ binding site (77). The HDX of this proposed Ca2+ binding region is 
A 
Figure 23; Overlay of TG2 and Factor XIII -A2. (A) The overlay of FXIII-A2 and the closed conformation of 
TG2. One monomer of the FXIII-A2 dimer is shaded while the other is (blue). The GOP-bound (closed) TG2 is 
(red) and the catalytic triad is (yellow sticks). (8) The overlay of FXIII-A2 and the open conformation of TG2 . 
One monomer of FXIII-A2 is shaded while the other is (blue). The TG-OON inhibited conformation ofTG2 is 
overlaid in (red) and the catalytic triad is (yellow sticks) . The overlay was performed using the MultiSeq tool in 
VMO(51) . 
65 
represented by 452 - 462, an alpha-helix that lay in a flexible region between the 
catalytic core and j3-barrel 1. The> 20 % protection observed in for 452 - 462 
supports the evidence of a noncanonical Ca2+ binding site in this region. 
In addition to the noncanonical Ca2+ binding site Lai et a/. reported that 
K468 is one of three lysine residues that, when acetylated , inhibit TG2 activity 
(87). The decrease in TG2 activity after acetylation was attributed to the inability 
of this flexible region to change conformation and allow for the open 
conformation. The a-helix 
character of 452 - 462 in TG-
DON inhibited TG2 extends C-
terminally when compared to 
GOP-bound TG2. This 
extension of a-helix character 
would allow for more intra-helix 
H-bonding thus decreasing the 
exchangeable protons. The 
452 - 462 region was 
represented by two peptides 
that shared 462 as their C-
terminus. Both peptides 
experienced the same amount 
protection, further supporting 
the evidence that the C-
Figure 24: Overlay of FXII I-A2 and the open conformation of 
TG2. One FXIII-A2 monomer (blue) was aligned with TG-OON 
(yellow) inhibited TG2 (red). The other FXIII-A2 monomer 
displays a surface projection emphasizing the interference 
between the FXIII-A [3-sandwich (surface) and the [3-barreI1 of 
TG2 in the open conformation. The overlay was performed 
using the MultiSeq tool in VMO(51) . 
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terminus is important for the observed protection. This helix lies on the backside 
of the 'hinge' during inhibition (opening) of TG2. Due to this placement it is not 
surprising that it would become more protected as the TG2 molecule opens. 
The conformational dynamics of Factor XIII has been well characterized 
by HDX and chemical modification techniques (43-44, 46, 60, 92). TG2 and the 
FXIII-A monomer share a high degree of sequence and structural homology 
(Figure 23). Due to differences in sequence coverage a direct comparison 
between TG2 and FXIII HDX was not possible. One region of FXIII which has 
received lots of attention is the exposure of the dimer interface during activation 
and inhibition (43-44). The equivalent residues on TG2 were not observed. 
There has been debate as to whether FXIII-A2 undergoes a large conformational 
change when inhibited like that reported for TG (46, 49). The increase of 
exposure around the FXIII-A2 dimer interface would seem to support this 
hypothesis; but, if it is assumed that FXIII-A2 opens in a manner similar to TG2, 
it would have to overcome substantial steric hinderance between the l3-sandwich 
region of monomer 1 and the l3-barrel1 of monomer 2. When the FXIII-A2 dimer 
is overlaid on the open conformation of TG2 this blockage between the opposing 
monomers of FXIII become evident (Figure 24). Komaromi, et al. have 
attempted to model FXIII-A2 undergoing an open conformation and reported that 
they had to "eliminate two conformational bumpings by making cuts in the 
structure and manually deriving new positions for them" (93). Although the data 
provided to date would not suggest a major conformational change in FXIII-A2 
during activation, more work needs to be done to place any certainty on this 
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hypothesis. Since 2007 when TG2 was captured in the open conformation there 
have already been antibodies designed for the detection of the open 
conformation (Zedira, Darmstadt, Germany). The possibility of trapping FXIII-A2 
in a particular conformation via specific antibodies or pharmaceutals would open 
new avenues for dealing with aberrant coagulation. 
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CHAPTER IV 
UTILIZATION OF HDX TECHNOLOGY TO ELUCIDATE THE FXIII A 
RESIDUES CRUCIAL FOR HETEROTETRAMER FORMATION WITH FXIII B. 
Introduction 
In plasma, factor XIII is a protransglutaminase with a tetrameric structure 
consisting of two A subunits and two B subunits (FXIII-A2B2), where the B 
subunits act as a carrier for the catalytically active A subunits. All FXIII-A in 
plasma is found in the complexed A2B2 form, but the B2 subunits are in excess 
and about 50% are in the uncomplexed B2 form (94). To date there is not a 
crystal structure available for FXIII-B, but by electron microscopy they appear as 
thin flexible and kinked fibers (95). Factor XIII-B is a glycoprotein which contains 
8.5% carbohydrate and has a molecular mass of -80 kDa. Structurally, the B 
subunit contains 10 "sushi-domain" repeats (Figure 25), each of which consist of 
60 amino acids and 2 disulfide bridges (96-97). 
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Figure 25: Primary sequence of FXIII B2 illustrating the 10 sushi-domain repeats each containing 60 
AA and 2 disulfide bonds. This research was originally published in The Journal of Biological Chemistry. 
Ichinose, A., Bottenus, R.E., Davie, E.W. Structure of Transglutaminases. Journal of Biological 
Chemistry. 1990; 265:23 13411 - 13414. © the American Society for Biochemistry and Molecular 
Biology (96). 
Factor XI II-A exists as the -320 kDa A2B2 heterotetramer with a 
concentration of 14-28 jJg/ml in plasma. The apparent binding constant for the 
association of A2 and B2 subunits was determined to be 4x1 07 M-1 (Kd = 0.025 
jJM)(25). Souri recently utilized several truncated forms of FXIII-B which 
contained different regions of the molecule (eg. sushi domains 1-9, 1-5, 1-4,5-
10, etc.) to identify the sushi domains responsible for dimer (B2) formation and 
heterotetramer (A2B2) formation. The fourth and ninth domains are crucial for 
dimer formation and the first sushi domain on the N-terminus is needed for 
heterotetramer formation (Figure 23) (98). The exact residues on FXIII-B that are 
important to the B2-dimer and A2B2-tetramer formation have not been 
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Figure 26: Cartoon model of FXIII 8 homodimer illustrating sushi-domains 4 and 9 (yellow) which 
are crucial for FXIII 82 dimer formation and domain 1 (red) which is utilized in heterotetramer 
formation with FXIII A2. Figure used from (98) . 
determined. When complexed with FXIII-B, FXIII-A is stabilized in plasma 
increasing its half-life. The concentration of FXIII-A decreased 40% after 2 hr 
incubation at 37 °G. Further evidence of the stabilization of FXIII-A is the 
resistance to proteolytic attack by trypsin and thrombin observed when FXIII-A is 
bound to FXIII-B (99). When bound , the protective effects of the B-subunit are 
well documented, but the FXIII-A2 residues required for tetramer formation have 
yet to be elucidated. It is hypothesized that the beta-barrels playa major role in 
the tetramer formation because when truncated the tetramer is not observed by 
co-immunoprecipitation with an anti-XIII-B antibody (99). 
In the current study hydrogen-deuterium exchange coupled with MALDI-
TOF-MS was utilized to unveil the residues on FXIII-A that become less 
accessible to solvent when it associates with the B2 subunit forming the A2B2 
heterotetramer. Monitoring FXIII-A solvent protection by HDX aided in painting a 
more complete picture of how FXIII-A and FXIII-B interact in solution. These 
experiments demonstrated that although FXIII-B2 incurs FXIII-A2 proteolytic 
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resistance 14 % sequence coverage was still observed. Even with decreased 
sequence coverage it was demonstrated that much of the FXIII-A molecule 
becomes protected in the presence of FXIII-8, but significant protection is 
observed around the dimer interface and both of the beta-barrels. This evidence 
supports earlier reports of ~-barrel involvement in heterotetramer formation (98-
99). 
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Materials and Methods 
Factor XIII A2 and Factor XIII 8 2 Preparation 
Recombinant human cellular FXIII A2 was generously provided by Dr. Paul 
Bishop (ZymoGenetics, Inc., Seattle, WA). After reconstituting the lyophilized 
FXIII in 18 MO deionized water, FXIII was buffer exchanged into 25 mM Tris-
base at pH 7.4. The concentration of FXIII was determined on a Cary 100 UV/vis 
spectrophotometer. The absorbance was monitored at 280 nm and 
concentration calculated with the FXIII extinction coefficient of 1.49 ml/mg cm. 
Aliquots (12 IJI) of 34 IJM FXIII in 25 mM Tris-base were stored at -70°C until 
future use. 
A 200 IJg ampoule of recombinant human FXIII B2 (Zedira, Darmstadt, 
Germany), lyophilized in the presence of 25 mM Tris, was resuspended with 18 
MO deionized water to a concentration of 24 IJM. Aliquots of 10 IJI were prepared 
and stored at -20°C until use. 
HDX Experimentation 
Hydrogen deuterium exchange was utilized to elucidate points of contact 
between the FXIII A2 and FXIII B2. An aliquot of 24 IJM FXIII B2 and 34IJM 
FXIIIA2 were allowed to come to room temperature. For analysis of FXIII A2 in 
solution, 6 IJI FXIII was added to 10 IJI 25 mM Tris for a final concentration of 13 
IJM FXIII-A. To allow for FXIII A2 and FXIII B2 binding before HDX, 6 IJI 34 IJM 
FXIII A2 was added to 10 IJI 24IJM FXIII B2 yielding 13 IJM FXIII A and 15 IJM 
FXIII B in solution. All assays were then allowed to incubate for 20 minutes on 
ice. Following incubation, the assay tubes were then evaporated to dryness in 
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the SpeedVac and then HOX was performed on the dry samples. The following 
HOX protocol was then adapted from methodology established in the Komives 
laboratory (65-66). The dry FXIII aliquot was allowed to reach room temp before 
12 JJI of 99.996% 020 (Cambridge Isotope Laboratories) was added yielding a 
final working concentration of 17 JJM FXIII A and 20 JJM FXIII B. The samples 
were incubated at room temperature for 10 minutes before the HOX was 
quenched by adding 120 JJI of chilled 0.1% TFA at pH 2.5. The quenched 
reaction was then immediately transferred to a tube containing activated pepsin 
bound to 6% agarose (Thermo Scientific, Rockford, IL). Pepsin digestion 
occurred for 10 min on ice. Following digestion, the reaction mix was centrifuged 
for 30 sec to separate the FXIII digest from the pepsin beads. Three 8.2 JJI 
aliquots were immediately frozen in liquid N2 and each reaction condition was 
performed three times. 
HDX Analysis 
A FXIII(a) HOX aliquot was thawed at room temperature and immediately 
mixed with an equal volume of 10 mg/ml a-cyano-hydroxycinnamic acid matrix 
(a-CHCA) (Aldrich) in 1:1:1 ethanoIlCH3CN/0.1%TFA at pH 2.2, and 0.5 JJI was 
spotted on a chilled MALOI plate. The sample spot was then quickly dried by 
placing the MALOI plate into a SpeedVac. The plate was then immediately 
inserted into the MALOI-TOF-MS (Voyager DE-Pro, Applied Biosystems). 
Spectra were collected in reflector mode with 256 shots/spectrum. All peptides in 
the peptic digest were previously identified by Brian T. Turner, Jr. (45) and/or 
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confirmed by MS/MS analysis on an Applied Biosystems 4700. Peptide 
identification was confirmed through observing the same peptide sequence in 
multiple independent digests, with an ion score preferably above 20 (peptic 
peptides Appendix C). After digestion by pepsin, the FXIII A2 peptides identified 
represent 40 % coverage. These peptides focus on key FXIII regions found 
within the ~-sandwich, the catalytic core, and the ~-barreI1 region. Additional 
studies with acid dependent type XIII protease did not significantly improve 
sequence coverage. All the MALDI spectra derived from pepsin digests were 
analyzed using Data Explorer (Applied Biosystems) and calibrated using two 
singly protonated reference peptides; monoisotopic mass 850.4787 Da (residues 
535-541) and quadraisotopic mass of 1375.7097 Da (residues 220-230). 
Deuterium incorporation for each isotopic cluster was quantified as 
described by Sabo et a/. (67). To determine the change in deuteration for FXIII 
under different conditions the percent deuteration for each peptide was 
calculated using equation 1 (page 23). In accordance with previous HDX data 
analysis, percent differences greater than 4.5 % are considered significant (45, 
67-69), 3-4.5 % is moderate and < 3 % is modest. 
Native Gel 
To mimic the HDX conditions, prior to running on the gel, 3 j..Il 34 j..IM FXIII-
A was added to 5 j..Il 24 j..IM FXIII-B. A 13 j..IM FXIII-A and 15 j..IM FXIII-B aliquot 
was also prepared and all samples incubated for 20 minutes on ice. Each 
sample was then added to 16 j..Il sample buffer (63 mM Tris pH6.8, 10 % glycerol 
and 0.05 % bromophenol blue). The samples were electrophoresed using a 4.0 
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% polyacrylamide stacking gel (125 mM Tris-base, pH = 6.8) on a 7.5 % 
polyacrylamide resolving gel (375 mM Tris-base, pH=8.8) and a running buffer of 
5 mM Tris Base and 38.4 mM glycine pH = 8.3. The gels subsequently were 
stained with a 0.1 % Coomassie blue solution containing 40 % Methanol and 10 
% Acetic acid. A Gel Doc™ XR+ System (Bio-Rad, Hercules, CA) was then 
utilized for gel imaging. 
76 
Results 
FXIII-B induced proteolytic resistance 
All HDX that have been run in our lab to th is point have included proteins 
with a molecular weight of no more than -160 kDa (FXIII-A = -80 kDa) . The 
FXIII-A2B2 heterotetramer has a molecular weight of -320 kDa (4 x -80 kDa). 
This increase in total protein mass along with the known proteolytic resistance of 
FXIII-A in the presence of FXIII-B (98-99) led to an exploratory experiment to 
determine the feasibility of performing HDX on this system. Following a 10 
minute pepsin digest mimicking HDX conditions. peptides produced were 
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Figure 27: Representative spectra for FXII I-A2 (A) , FXIII-B2 (B) and FXIII-A2B2 (C) following pepsin 
digestion. 
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monitored for FXIII-A, FXIII-B and FXIII-A2B2 on the MALDI-TOF-MS (Figure 
27 A-C). At 13 IJM, FXIII-A produced pepsin digest with many clear and 
identifiable peaks (Figure 27A). FXIII-B contains 2 disulfide bonds per sushi 
domain which infers an innate proteolytic resistance. Due to the proteolytic 
resistance, only two major peaks (m/z = 1350.65 and 2039.95) are found in the 
FXIII-B pepsin digest (Figure 27B). FXIII-B did elicit proteolytic protection upon 
FXIII-A when in the heterotetramer form as seen in Figure 27C. The intensity of 
the most abundant ion (m/z = 1216.70) in Figure 27A is 5 fold higher than that for 
the spectra representing 13 IJM FXIII-A in the presence of 15 IJM FXIII-B. 
Suppression within the FXII I-A2B2 pepsin digest resulted in a decrease in 
sequence coverage for the HDX. After digestion by pepsin, the FXIII-A2 peptides 





180 121 IVSEL SGKW GAKIVM Y VAVWTPYGVL 
181 YILfNPWCED DAV IG VIr EDGILDTC 240 
241 NAKD DEGVLVGSWD NIYAYGVPPS AWTGS'ID 300 
301 rlVfAGV fNTf fS AHDNDANLQM DlfLEEDGNV 360 
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Figure 28: FXIII peptides observed by MALDI-TOF-MS after 10 minute 
pepsin digestion. The magenta and green represent peptides observed 
for FXIII-A2 (40 % coverage). The green peptides represent those 
observed in FXIII-A2B2 digests (14 %). 
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found within the 13-
sandwich, the catalytic 
core, and the l3-barrel 1 
region. Although the 
peaks from the FXIII-A2 
digest are observed in 
the FXIII-A2B2 digest, 
there is a large 
decrease in sequence 
coverage due to lower sensitivity as well as peak interference (overlap of 
unidentified peptides) . Following pepsin digestion, FXIII-A2 sequence coverage 
reduces to 14 % when bound to FXIII-B2 (Figure 25). 
Native Gel - Heterotetramer confirmation 
FXIII-A2 has a high affinity for FXIII-B2 (Kd = 25 nM) and is found almost 
exclusively as a FXIII-A2B2 heterotetramer in plasma. To confirm FXII I-A2B2 
formation for HDX analysis native (no SDS) PAGE was utilized . By mirroring the 
solution conditions for HDX, native PAGE identified FXIII-A2 and FXIII-B2 dimers 
as well as FXIII-A2B2 heterotetramer formation in solution (Figure 26) . FXIII-A2 
migrated the furthest and FXIII-B2 having a similar molecular weight migrated in 
almost as far as FXIII-A2. The FXIII-A2B2 complex was confirmed in the higher 
molecular weight (slower migrating band) . 
After confirming FXIII- A2B2 
FXIII-A, FXIII-B, FXIII-A,B, 
formation , HDX analysis was 
performed to monitor the regions of 
FXII I-A2 which become more protected 
97.4 kDa 97.4kDa in the presence of FXIII-B2. Due to the 
interactions between FXIII-A2 and 
Figure 29: Native PAGE illustrating the formation 
of FXIII-A2B2. Molecular weight standards are FXIII-B2 during heterotetramer 
marked (97.4 kDa) . 
formation , there was a substantial 
decrease in sequence coverage. Even with this decrease in coverage, regions of 
FXIII-A2 important for heterotetrmer formation were monitored, for the first time, 
using HDX coupled with MALDI-TOF MS. 
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FXII/-A2B2 HDX Analysis 
To date FXIII-A2B2 has yet to be crystallized; therefore, HDX was utilized 
in an effort to ascertain the regions of FXIII-A2 that are involved in heterotetramer 
formation with FXIII-B2. Since Ca2+ is a FXIII-A2 cofactor that aids in FXIIIA2B2 
separation and FXIII-A2 activation, all studies were run in the absence of divalent 
metal cations(39, 58). For the current conformational studies on FXIII A2B2 Table 
4 displays changes in deuterium incorporation of FXIII-A2 zymogen compared to 
FXIII-A2B2. The total deuterium incorporated for each pepsin-derived peptide is 
displayed in Figure 30. 
The ~-sandwich region of FXIII-A2 contains the activation peptide as well 
as peptide 4, a Gin 
substrate recognition 
region. Due to the 
decrease in FXIII-A2 
sequence coverage, there 
were not any quantifiable 
peptic peptides within the ~-
sandwich region. The 
catalytic core contains 
several regions of interest. 
Another important putative 
Gin substrate recognition, 
peptide 7 (190-230), is 
Table 4: Changes in Percent Oeuteration: FXIII-A2B2 relative to 
FXIII-A2 zymogen a 
Residues Theo. Dmax 6 FXIII-A2B2 
137-144 7.90 -0.8 
145-159 15.58 -1.6 
220-230 12.31 _5.8d 
240-247 7.50 -16.7 
298-305 7.50 -6.4 
325-338 14.40 0.9 
328-338 9.5 -2.4 
535-541 6.5 -1.2 
607-619 12.80 -14.5 
632-646 14.70 -10.6 
a The % change for a particular peptide was calculated by the 
following equation: % difference = ((0 - OFxlII)/Omax) x 100 % , 
where 0 is the amount of deuterium incorporated in FXIII with 
metal, OFXIII is the amount of deuterium incorporated in the 
zymogenic state (no metal), and Omax is the theoretical 
maximum number of exchangeable protons within the indicated 
peptide. b The maximum number of exchangeable protons within 
the indicated peptide, assuming 100 % deuteration. This value 
accounts for all exchangeable backbone amide protons and a 
slight fraction of N-terminal, C-terminal, and side chain 
exchangeable protons, which are dependent on the final 
percentage of 020 in solution under quench conditions (-4.5 %). 
A fully deuterated peptide would theoretically have acquired this 
amount of deuterons. C The values in bold represent significant 
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Figure 30: The number of deuterons incorporated after 10 min at 37°C for FXIII-A2 (Blue) and 
FXIII-A2B2 (Red) Error bars represent the standard deviation of the mean for 3 independent 
trials. . 
found in the catalytic core(71) . In the peptide 7 region , 220-230, FXIII-A 
experienced significant 5.8 % protection from solvent when bound to FXIII-B. 
One of the regions which displayed the most protection when bound to FXIII-B 
was the dimer interface. FXIII-A (240-247), underwent a 16.7 % decrease in 
solvent accessibility. There were two other regions of the catalytic core 
represented (298-305) which showed a 6.4 % decrease in solvent accessibility 
and (325-338) which did not change significantly. FXIII-A peptide 325-338 was 
the only peptide quantified that displayed an increase (0.9 %) in HDX exposure. 
Peptide 328-338 found within 325-338 experienced 2.3 % protection, thus 
residues 325,326 and/or 327 must be exposed to explain the 0.9 % exposure of 
325-338. 
The p-barrels have always been poorly represented during HDX analysis 
(43-44, 60) , but they appear to be quite important for FXIII-A2B2 heterotetramer 
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formation. Protection within the FXIII-A2 J3-barrel 1 is evident in the 14.5 % 
protection at peptide 607-619. This large increase in protection also carries over 
into J3-barrel 2 where peptide 632-646, found on the N-terminal end of a 




Factor XIII has been studied extensively over the past 30+ years and the 
knowledge gained is extensive. Ironically very little has been done to determine 
how FXIII-A and FXIII-B interact. The recent work of Souri et a/. has shed new 
light on the sushi domains that are essential for FXIII-B2 dimer formation as well 
as FXIII-A2B2 heterotetramer formation (98). The FXIII-A regions necessary for 
heterotetramer formation have also been investigated and it was determined that 
the j3-barrels play an integral role (99). These studies have aided in generating a 
better understanding of FXIII- A2B2 formation but there still needs to be more 
work done to identify the binding epitopes involved on both FXIII-A and FXIII-B. 
The preliminary experiments to determine feasibility yielded evidence that 
FXIII-B is inherently resistant to pepsin proteolysis. After 10 min digestion on ice, 
FXIII-B only produced two quantifiable peptides (m/z = 1350.65 and 2039.95). 
This was promising considering that they did not overlap with any of our known 
peptic peptides produced in FXIII-A. Although the digest containing only FXIII-B 
did not produce any peptides that overlapped with FXIII-A digests, there were 
some peaks lost in the FXIII- A2B2 digest due to suppression and/or overlap of 
unidentified peptides. The protective effect of FXIII-B on the proteolytic action of 
pepsin on FXIII-A was observed in all FXIII-A2B2 digests. FXIII-B has been shown 
to stabilize FXIII-A in vitro (98-99). FXIII-B protected wild type and, to a lesser 
extent, Y283C FXIII-A from trypsin digestion, but this protection was not seen in 
a 1464stop mutant which does not contain the j3-barrels (99). A decrease in 
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FXIII-A proteolytic degradation due to heterotetramer formation was not only 
observed with trypsin, but also with the more unspecific proteinase K (98). The 
intensity of FXIII- A2B2 pepsin digests decreases nearly 5 fold in comparison to 
FXIII-A2. This signal suppression can be attributed in part to the proteolytic 
resistance of FXIII- A2 when associated with FXII I-B2. The protective effect of 
FXIII-B induced a decrease in digestion efficiency leading to a decrease in FXIII-
A sequence coverage from 40 % to 14 % (Figure 31). 
Once it was determined that HDX was possible with the FXIII- A2B2 
complex, a native gel was 
utilized to confirm 
heterotetramer formation . 
FXIII-B2 was the smallest of 
the components and thus 
migrated the furthest. FXIII-
A2 produced a nice band 
just above that of FXIII-B2 
and heterotetramer 
formation is confirmed in 
the slower migrating FXIII-
A2B2 band (Figure 26). A 
Figure 31: Illustration of FXIII-A2B2 HDX sequence coverage. 
FXIII-A2 (1 F13)is represented by the ribbons. The cartoon peptides 
represent 14 % of the molecule. Protection is noted in (blue), 
significant protection (purple) and exposure (red) . Image was 
constructed utilizing VMD (51) 
1:1 ratio of FXIII-A2 to FXIII-B2 has been confirmed in previous studies (98-
99) .Therefore, a faint FXIII-B2 band is observed in the FXIII-A2B2 lane due to a 
small excess of FXIII-B2 (15 !-1M) versus FXII I-A2 (13 !-1M). 
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The util ization of 
HDX to monitor the 
conformational dynamics of 
FXIII-A2 when associated 
with FXIII-B2 allows for 
identifying regions that 
become protected due to 
the heterotetramer 
formation. It has been 
reported that the ~-barrels 
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Figure 32: Representative HDX Spectra. The three 
representative FXII I-A2 spectra illustrate the isotopic clusters of 
peptide 240-247 after 10 min. HDX. The FXIII state is listed in 
the figure . This peak cluster represents a peptide found on the 
FXIII-A2 dimer interface. Protection due to heterotetramer 
formation was observed for FXIII-A2B2. 
A2B2 formation (99), but it is unknown as to how the rest of the FXIII-A2 molecule 
is affected. The sequence coverage of FXIII-A2 can be seen in Figure 31. 
Nearly the whole molecule becomes protected when interacting with FXIII-B2. 
Within the catalytic core there were three peptides which underwent 
significant (>4.5 %) protection. The first regions of importance was the putative 
Gin binding site, peptide 7 (190-230) , represented by peptide 220-230. This 
region has been shown to display exposure when activated proteolytically and 
non-proteolytically, in the presence of physiological concentrations of Ca2+ , and 
when inhibited (43-44) . It is thought that FXIII-A2B2 is associated with fibrinogen 
in plasma. By limiting substrate recognition at peptide 7, FXIII-B could be 
protecting against FXIII-A2 utilizing the fibrinogen as substrate. One peptide falls 
along the dimer interface (240-247) and it becomes substantially protected in the 
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heterotetramer form as seen by the isotopic cluster shift to a lighter mass (Figure 
32). The dimer interface becomes more exposed as FXIII-A2 becomes activated 
so therefore, by remaining protected, FXIII-B2 is limiting the ability of FXIII to 
aberrantly become activated in plasma. The catalytic cysteine was not 
represented, but peptide 298-305 resides 9 residues N-terminally were protected 
6.4 % yet again illustrating the protective nature of FXIII-B2 on FXIII-A2. 
Prior to the elucidation of the FXIII-A2 crystal structure, Lai et al. utilized 
several different C-terminally truncated FXIII-A mutants to define the minimum 
structure required for transglutaminase activity (56). When truncated at K513 
and A502, FXIII-A affinity for small Gin containing substrates only decreases 2 
fold, but the turnover rate experiences a 4 fold decrease. This decrease in 
turnover when the l3-barrels are truncated and complete abolishment of activity 
when truncated at the Ca2+ binding site demonstrates not only the importance the 
l3-barrels play in primary amine recognition/turnover, but also the necessity of an 
intact Ca2+ binding site within the catalytic core (56). Souri et a/. has nicely 
demonstrated the importance of the l3-barrels in heterotetramer formation (98-
99). FXIII-A 1464stop as well as two mutants that excluded either l3-barrel 1 or 13-
barrel 2 were all unable to form FXIII-A2B2 heterotetramers. In the present study 
607-619 in l3-barrel1 and 632-646 in l3-barrel2 experienced 14.5 and 10.6 % 
protection from solvent when bound to FXIII-B. These results further 
substantiate the hypothesis that the l3-barrels are essential for heterotetramer 
formation and give specific residues involved in the FXIII-A2 - FXIII-B2 
interaction. 
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It is known that in plasma FXI II-A2B2 is largely associated with fibrinogen 
(100). The binding site of fibrinogen on FXIII-A and/or FXIII-B has yet to be 
identified . Lai et al. demonstrated that even when truncated at Y481, FXIII-A still 
binds to fibrinogen even though it has lost> 99 % of FXllla activity (56). It was 
proposed that the FXIII-A fibrinogen binding site was independent of the 
substrate recognition site (71). The protection seen in the l3-barrels would allow 
for FXIII-A2 - FXIII-B2 interactions while still bound to fibrinogen. 
Although FXIII-B has not been crystallized, 132-glycoprotein I (132-GPI) 
contains similar short 
consensus repeats also 




similarity between the 4 
sushi domains of 132-GPI 
and the sushi domains in 
3 other proteins (r.m.s.d 
< 2.5 A) (101). Using 
the sushi domains of 132-
GPI as a model, it was 
38ft. 
Figure 33: 132-glycoprotein I - Representative sushi domain . The two 
representative sushi domains are illustrated as (cyan) cartoon ribbons 
with the four cysteines involved in disulfide bond denoted as (red) 
sticks. Each sushi domain is - 38 x 17 x 20 A so therefore, the 10 
FXIII-8 sushi domains would span -380 A(101). 
determined that a typical sushi domain is 38 A x 20 A x 17 A (Figure 30), 
therefore, an elongated FXIII-B would be -380 A in length (101). The FXIII-A2 
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dimer has a length of -102 A and each ~-barrel is approximately the same size 
as a sushi domain (41-42). If FXIII-B2 took the orientation proposed by Souri et 
al. (Figure 30) where the first sushi domain of each FXIII-B was interacting with 
the ~-barrels and domains 4 and 9 were involved in FXIII-B2 dimer interactions, 
FXIII-B2 would stretch> 380 A. Since the FXIII-A2 dimer is only 102 A, the FXIII-
B2 dimer would create a D-shaped loop tethered by the first sushi domain to 
opposing FXIII-A2 ~-barrels. Judging by the HDX results, the FXIII-B loop elicits 
protection across FXIII-A2, but solvent protection is primarily observed at the ~­
barrels (the putative FXIII-B2 binding site) and the dimer interface. 
HDX has allowed for the first glimpse of the regions of FXIII-A2 that play 
an integral role in FXIII-A2B2 heterotetramer formation. It has long been known 
that when bound to FXIII-B2, FXIII-A2 is protected from proteolytic degradation. 
The near global HDX protection observed in FXIII-A2 in the FXIII-A2B2 
heterotetramer, brings forth new evidence of the protection bestowed upon FXIII-
A2. The data presented here further emphasizes the importance of the FXIII-A2 
~-barrels in the interaction between FXIII-A2 and FXIII-B2. These studies aid in 
presenting a clearer picture of FXIII-A2B2 heterotetramer formation. A better 
understanding of the residues involved in this interaction could potentially be 
used to promote either the FXIIIA2B2 formation for prevention of aberrant clotting 
or the release of FXIII-A2 for pro-coagulant activity. 
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Chapter V 
DEVELOPMENT OF A FIBRINOGEN ALPHA-C EXPRESSION SYSTEM 
UTILIZING MINIMAL MEDIA AND SUBSEQUENT ALPHA-C STRUCTURAL 
ANALYSIS VIA NMR 
Introduction 
Factor XIII works in concert with thrombin (1Ia) and fibrinogen during the last 
steps of the blood coagulation cascade. Fibrinogen (Figure 34) a 340 kDa 
A 
B 1 
Figure 34: Schematic of fibrionogen and the dissociation 
of the aC domain when converted to fibrin(102). A. A 
Fibrinogen molecule with the D-E-D nodules linked by the 
coiled coil connectors and the aC domains interacting with 
each other and the central E domain via the B peptides. 
Residue 374 has been labeled to give a point of reference. 
B. Diagram of a fibrin protofibril where the aC domains 
have dissociated after Fbg peptides A and B (marked with 
* in A) were cleaved by lIa. 
protein consists of three chains 
(Aa, BI3 and y) forming the 
homodimer (AaBI3Y)2. The rod-
like dimer of trimers has a central 
E-region which contains the N-
termini of the fibrinogen chains. 
The two Aa, BI3 and y chains 
extend in opposing directions 
from the E-region in a coiled coil 
and terminate in two globular 0-
regions . Thrombin is responsible 
for cleaving fibrinopeptides A and 
B (marked with * in Figure 34 A) from the N-termini of the Aa and BI3 chains to 
form fibrin I and fibrin II respectively (103) . The resultant fibrin monomers can 
align E and D-regions to form a soft clot. Thrombin, as mentioned previously, is 
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also responsible for activating FXIII by cleaving the activation peptide at R37-
G38. Fibrin acts as a cofactor for the activation of FXIII by decreasing the 
concentration of Ca2+ needed for FXIII-A2 to dissociate from FXIII-B2 and also 
accelerating the activation peptide cleavage by lIa (29, 31, 74). 
The C-terminal portion of the Aa chain extends beyond the D-region to 
form the aC-domain (104). The aC-domain (221-610) interacts intramolecularly 
with each other and the central E-region of fibrinogen until fibrin assembly. 
During assembly, they dissociate from the E-region and interact intermolecularly 
promoting lateral aggregation of protofibrils in a process catalyzed by FXIII (105-
107). The process of aggregation begins with v-chain dimerization of fibrin and is 
followed by a-chain polymerization (108). The sites of intramolecular cross-
linking on the aC-domain are: Gln-Aa-328, Gln-Aa-366, Lys-Aa-508, Lys-Aa-556 
and Lys-Aa-562 (109). There are several crystal structures of fibrinogen, but the 
aC-domain has been elusive in structural characterization (110-111). The aC-
domain, primarily bovine 374 - 538 (human equivalent 392 - 610) has been 
studied extensively by NMR. These studies have led to the discovery of a ~­
hairpin which is held together by a disulfide linkage C423 - C453 at its base 
(102, 112-113). The crosslinking of fibrin monomers by FXIII-A2 is critical to the 
formation of stable insoluble clots, yet to date there have not been any studies 
exploring the structure of the aC-domain in the presence of FXIII-A2. 
Fibrinogen aC-domain (233-425) expression 
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In order to monitor the conformational dynamics of the fibrinogen aC-
domain in the presence of FXIII-A2, aC-domain (233-425) was expressed in E. 
coli. The gene coding for aC (233-425) was cloned into the pGEX-6P-1 vector 
which has a glutathione-S-transferase (GST) tag as well as ampicillin resistance. 
There were no mutations made to the primary sequence, so the purified DNA 
was transformed into DH5a E. coli to create DNA stocks. After collecting DNA 
via mini prep, the DNA was subsequently transformed into BL21 Gold (DE3) cells 
for protein expression. The BL21 Gold (DE3) competent cells are the suggested 
host for pGEX-6P-1 plasm ids. 
Once aC expression and purification was confirmed (Figure 35) using 
conventional methods (LB broth), a method for protein expression was 
developed utilizing minimal media. Minimal media allows for growth with only the 
essential nutrients. Providing only the essential nutrients allows for maximizing 
the incorporation of isotopic labels 
not found in standard media. To 
enable future studies using NMR, it 
was imperative to develop a 
method of expressing the aC (233-
425) domain in the presence of 
isotopically labeled media C5N, 13C 
31 .0 kDa 
21.5 kDa 
14.4 kDa 
Figure 35: aC Domain (233-425) Purification 
Confi rmation. This is a representative PAGE gel 
confirming the presence of aC after expression in BL21 
Gold cells and purification using GST affinity columns on 
an AKTA prime system. 
and/or 2H). Due to the high cost of isotopically labeled nutrient sources, there 
have been several methods designed to maximize growth with limited nutrients 
(114-116). The aC domain (233-425) was successfully expressed in BL21-Gold 
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cells using a method adapted from Marley et. al and Paliy, et. al with minimal 
media containing 15NH4CI (114-115). 
NMR methods for analyzing unstructured proteins 
Over the past few decades there have been tremendous advancements in 
NMR technology allowing for protein analysis. NMR has situated itself at the 
forefront as a method of elucidating protein structure, monitoring molecular 
dynamics, ligand-receptor interactions, and kinetics (117). To date over 8300 
NMR-derived protein structures have been submitted to the Protein Data Bank 
(PDB). One benefit to NMR analysis of proteins is the ability to gather structural 
information that is not available through contemporary crystallization techniques. 
Proteins that do not crystallize well such as membrane bound proteins or 
proteins that contain flexible regions (118) that are not visible using X-ray 
technology are of particular interest. 
Of particular importance in the initiation of protein structural analysis is 
the 1 D 1H NMR and the 15N-HSQC (Heteronuclear Single-Quantum Correlation) 
spectrum (119). The 1D 1H NMR simply displays signals for each proton and the 
2D 15N-HSQC shows a unique signal for each proton bound to a 15N. In a 2D 
15N-HSQC experiment, the applied magnetization is transferred from any 1H 
attached to a 15N nuclei, to the 15N through scalar coupling (J-coupling). The 
chemical shift then evolves and is detected after it is transferred back to the 1H 
(Figure 36). The resulting 2D spectrum contains a 15N axis and a 1H axis, and 
the 1H chemical shifts depend upon the chemical environment (electron density) 
surrounding it. Therefore each backbone amide (except proline) gives rise to a 
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Figure 36: Representative tripeptide displaying the magnetization transfer during a 15N_HSQC. The 
amide Nand H are red to illustrate the atoms involved in the transfer of magnetization . The arrow 
indicates the travel of energy from the 1H to the 15N then back to the 1H for detection . The 'CR' 
represents the amino acid side chains. 
unique resonance at the 15N and 1H frequencies for that individual amide group. 
The more shielded the amide is the more its signal will shift upfield and vice 
versa. By observing the dispersion of the 15N-HSQC chemical shifts, one can 
estimate whether a protein is unstructured or contains any defined structure. 
The aC domain (233-425) contains 2 glutamine residues Gln-Aa-328 and 
Gln-Aa-366 that are known substrates for FXIII-A2 during blood coagulation. 
Prior to transglutmainase activity, the aC domain of fibrin is also known to 
associate with FXIII-A2B2. The aC domain is believed to be unstructured in 
solution therefore eluding crystallography (40-41). The minimal binding domain 
of hypoxia-inducible transcription factor HIF-1a is an example of an unstructured 
protein in solution that adopts a structure after it binds, with nM affinity, to CBP 
(CREB-binding protein) (118, 120) . This conformational change in HIF-1a is 
easily observed through the dispersion of the 15N-HSQC chemical shifts after 
addition of CBP to 15N labeled HIF-1a. Using these same techniques the aC 
domain (233-425) of fibrin was expressed in minimal media to produce 15N_ 
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labeled protein. 15N-HSQC was then utilized to monitor peak dispersion 
(structure formation) when FXIII-A2 was added to the solution. 
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Materials and Methods 
Preparation of aC domain (233-425) DNA stocks 
The aC-domain (233-425) pGEX-6P-1 plasmid (GE Healthcare, 
Piscataway, NJ) DNA was a generous gift from Helen Philippou, Robert Ariens 
and Kerrie Smith at the University of Leeds, Leeds Institute of Genetics Health 
and Therapeutics (121). It should be noted that all materials used during 
transformation, expression and purification were sterile. DH5a E. coli cells 
(Invitrogen, Carlsbad, CA) were transformed to build an aC (233-425) DNA 
stocks. The first step in transforming the DH5a cells was transferring -5 ng aC 
(233-425) DNA into a 50 1-11 aliquot of DH5a competent cells in a 1.5 ml tube. 
This DNAIE. coli mix was placed on ice and incubated for 30 min. Following 30 
min on ice the cells were heat shocked for 20 seconds in a 42°C water bath and 
then returned to the ice for an additional 2 min. The transformation was then 
brought to temperature with the addition of 950 1-11 37°C LB media (Appendix C). 
The cell mix was then incubated for 1 hr at 37°C while shaking at 225 rpm. After 
incubation, if transformation efficiency is low, the cells could be concentrated by 
spinning for 2 sec at 10,000 rpm and removing 500 1-11 supernatant prior to 
resuspending cells. In most cases this step was unnecessary and 75 1-11 of the 
transformed cells were plated on LB agar + Ampicillin plates (Appendix C). The 
plates incubated for 16 hr at 37°C. Following transformation, a single intact 
colony was utilized to inoculate 4 ml LB agar containing 100 I-Iglml Ampicillin. 
The 4 ml culture was incubated at 37°C with shaking at 225 rpm for 16 hr. The 
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DNA was then purified using the QIAprep Miniprep kit (Qiagen Inc., Valencia, 
CA). Following purification, the DNA concentration was determined using a 
Nanodrop ND-1000 Spectrophotometer (Thermo Scientific, Wilmington, DE). A 
typical DNA yield for an aC-DNA Miniprep was 60-80 ng/ml. Purified DNA was 
also sent for sequencing using pGEX-6P-1 3' and 5' primers (GE Healthcare, 
Piscataway, NJ). 
Transformation of aC domain (233-425) in BL21 Gold (OE3) cells 
Once DNA stocks were established, BL21 Gold (DE3) cells were utilized 
to express the aC-domain (233-425) for purification. A 1 - 2 1-11 aliquot totaling 10 
- 25 ng DNA was added to a 14 ml round bottom tube with 100 1-11 BL21-Gold 
(DE3) E. coli cells (Agilent Technologies, La Jolla, Ca). The BL21 cells were 
incubated on ice for 30 min then heat shocked in a water bath for 20 sec at 42°C. 
Following the 20 sec heat shock, the cells were placed on ice for additional 2 
min. The cells were then brought to temperature through the addition of 1 ml 
prewarmed (42°C) SOC media (Appendix C). After addition of SOC media, the 
cells (150 1-11) were then plated on LB agar + Ampicillin and incubated overnight at 
37°C. 
Following incubation, a colony of cells was transferred to 5 ml LB broth 
containing 100 I-Ig/ml Ampicillin. The liquid culture was placed in the incubator 
where the cells were incubated at 37°C for 16-20 hr and then utilized to establish 
BL21-Gold cell stocks. Stocks were made by adding 5 ml 50 % glycerol to the 
cells then aliquoting and storing them at -70°C for later use. 
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Expressing aC (233-425) in BL21 Gold (OE3) cells 
The expression of aC (233-425) in transformed BL21 stocks can take 
place in any number of volumes. For example sake the steps used for a 2 L 
culture are described. First a 200 ml starter (or seed) culture was grown 
overnight after inoculation with the frozen BL21 stocks. The starter culture 
consisted of 180 ml LB broth, 20 ml phosphate buffer and 200 1-11 100mg/ml 
Ampicillin (Appendix C). The following day prior to addition of cells, 1800 ml 
Terrific Broth, 200 ml phosphate buffer and 2 ml 1 OOmg/ml Ampicillin was 
prepared in a 4 L flask. An aliquot was taken and analyzed on the Cary 50 
UVNIS to establish a baseline (Asoo = 0). Once a baseline was established for T 
= 0, the 200 ml starter culture was added to the flask. 
The culture (2 L) was shaken (225 rpm) at 37°C until the absorbance (cell 
growth) A600 = 0.8 - 1.0. At which time 2.2 ml of 1 M Isopropyl ~-D-1-
thiogalactopyranoside (IPTG), a molecular mimic of a lactose metabolite, was 
added to the culture. The addition of IPTG triggers lac operon transcription on 
the pGEX-6P-1 plasmid leading to the over expression of aC (233-425). After 
addition of IPTG, the culture was shaken (180 rpm) at 30°C for 16 hours. The 
cells were then transferred to centrifuge bottles and harvested during sequential 
10 min spins at 5000 g and 4°C. The harvested cell pellets were resuspended in 
180 ml ice cold E. coli wash buffer (Appendix C) by stirring (800 rpm) for -40 
min. Lastly, the cell suspension was transferred to 50 ml conical tubes and 
centrifuged in a swinging bucket rotor 45 min at 5000 g and 4°C. The 
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supernatant was discarded and the cell pellets were placed at -20°C until 
purification. 
Expressing 15N_aC (233-425) in BL21 Gold (OE3) cells with Minimal Media 
For isotopically labeling aC (233-425) the transformed BL21 cells were 
grown in minimal media. The recipes used for M9 salts and M9 media were 
adapted from Marley et al. and Paliy, et al (114-115). The seed culture for 
minimal media expression was grown in standard LB broth. For a 2 L culture, 
two sterile 50 ml conical tubes containing 36 ml LB broth were inoculated with the 
frozen stocks of transformed BL21 cells. The starter culture was grown overnight 
at 37°C while shaking at 225 rpm. The following morning the two starter cultures 
were spun at 5000 g for 10 min and the LB broth was discarded. Being careful 
not to disturb the 
pellet, the pellet was 
washed 2x with 5 ml 
1X M9 salts (Table 
5). The pellet was 
Table 5: Components of 1 L 5x M9 salts and 1 x concentration. The 
mass needed for 1 L 5x M9 salts and the final salt concentration after 












then resuspended in 2 ml1 x M9 salts and transferred to 2 L of M9 media (Table 
5 and Table 6). Prior to addition of cells to the M9 media, an aliquot was taken 
and used to establish an A600 baseline. Cell growth was monitored and the cells 
were induced with the addition of 2 ml 1 M IPTG. The cells were then incubated 
overnight at 30°C while shaking at 180 rpm. The 2 L culture was then spun 
down, washed and spun down again before freezing in the same manner 
previously described for growth in LB broth. 
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Table 6: Recipe for M9 minimal media. This table outlines all the components added to 1 
L of M9 growth media. For each component, the volume added as well as the final 
concentration are given. 
Volume (ml) M9 Media component Final Concentration 
200 5x M9 salts 
1.00 1 M MgS04 
1.00 200 mM CaCI2 
4.00 aO.25 g/ml NH4CI 
0.05 20 % Thiamine HCI 
1.00 100 mg/ml Ampicillin 
40.0 20 % Dextrose 








a For expressing isotopically labeled proteins, 15NH4CI was utilized as opposed to NH4CI. 
Purification of aC (233-425) 
The aC (233-425) produced during growth in LB media or M9 media was 
purified using the same process. Hot water was run over tubes and a spatula 
utilized to help transfer the frozen pellets to a clean 500 ml beaker. The tubes 
were rinsed with and resuspended in ice cold PBS (4 ml PBS/100 ml culture - 88 
ml PBS for 2L). The cells were stirred gently at room temperature to resuspend. 
Once resuspended, 888 1-11100 mglml Lysozyme [1 mg/ml] (the [] indicate assay 
concentration) and 88.8 1-111 M OTT [1 mM] was added to the cell suspension 
and incubated at room temperature, stirring gently, for 30 min. The protease 
inhibitors listed in Table 7 were added to the cell suspension and incubated for 
30 min at 4 °C stirring gently. Following incubation with protease inhibitors, 222 1-11 
100 mM phenylmethylsulfonyl fluoride [0.5 mM] and 449 1-11 10% Sodium 
Deoxycholate were added and the cell mix was stirred for 30 more minutes. The 
addition of 20% Triton X100 [1%] was done forcefully then 47.3 1-1110mg/ml 
DNase 1 [5 I-Ig/ml] was introduced with 472.5 1-11 1 M MgCI2 [5 mM). This was 
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Table 7: The protease inhibitors utilized in during purification of recombinant protein. 







2 mg/ml Aprotinin 
1 mM Pepstatin A 







incubated for 10 min at 4°C with stirring then quenched with the addition of 1.15 
ml 0.5 M EDTA [6 mM]. The cell suspension was then transferred to centrifuge 
tubes and spun for 20 minutes at 22,000 g. The supernatant was filtered using 
0.22 IJm Supor machV 150 ml filter-flasks (Nalgene, Rochester, NY). 
The purification process takes advantage of GST that is co-expressed with 
the aC (233 - 425). Utilizing an AKTA prime system, with GST specific 
GSTrapTM HP Columns (GE Healthcare, Piscataway, NJ) the GST-aC was 
trapped on the column (Figure 37). After overnight digestion with PreScission 
Protease, 1 unit per 100 IJg protein, (GE Healthcare, Piscataway, NJ) the free aC 
(233 - 425) was eluted from the column. To ensure a clean sample for future 
NMR studies the unlabeled aC (233 - 425) product was cleaned using a 
Detergent Removal Spin Column (Pierce, Rockford, IL). The 15N aC (233 - 425) 
was dialyzed into 1 x PBS and all recombinant aC was concentrated using an 
Amicon Ultra centrifugal concentration devices MWCO = 10,000 (Millipore, 
Billerica, MA). The concentration was established using an extinction coefficient 
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Figure 37: Visualization of aC (233-425) purification following expression in BL21 Gold E. coli cells . 
A) There are two different schemes shown; one for eluting aC (233-425) still bound to the GST 
linker (steps 2 - 4), and the other describes an on column digest to elute just aC (233-425) from 
the GSTrap column (steps 5 - 9). Step (1) is the addition of cell lysate to the GSTrap (GST 
affinity column). For elution of the GST- aC conjugate, the column was rinsed (2) , and reduced 
glutathione is pumped across the column (3) releasing the GST-aC from the glutathione-
sepharose column material. The GST-aC (233-425) fraction is collected and stored at 4 · C until 
further analysis (4) . For on-column digests, after the addition of cell lysate the column was rinsed 
(5). PreScission protease was then added to the column (6) and allowed to incubate at 4 · C 
overnight (7). The following morning an additional GSTrap column was added to capture any 
possible GST that may be released (8) and the recombinant aC (233-425) was eluted and stored 
at 4 ·C until further analysis (9). 
B) Representative SDS-PAGE gel and Western Blot image. In the SDS-PAGE gel the green band 
represents aC (233-425) and the pink band GST- aC (233-425). The GST specific Western Blot 
is representative of a blot containing un-cleaved GST- aC (233-425). 
Adapted from GST Gene Fusion System Handbook (122) 
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SDS-PAGE and Western Blot 
All expression products were confirmed using SOS-PAGE. The 15 % resolving 
gel was prepared by combining 2.4 ml dH20, 2.5 ml 1.5 M Tris (pH = 8.8), 5.0 ml 
30 % acrylamide and 0.1 ml 10 % SOS. The acrylamide polymerization was 
initiated with the addition of 50 1-11 Ammonium Persulfate (APS) and 5.0 1-11 
Tetramethylethylenediamine (TEMEO). The 4.0 % stacking gel which was 
poured on top of the resolving gel consisted of: 6.1 ml dH20, 2.5 ml 0.5 M Tris 
(pH = 6.8), 1.3 ml 30 % acrylamide and 0.1 ml 10 % SOS. Once again, the 
polymerization was initiated with 50 1-11 APS and 10 1-11 TEMEO. Samples were 
mixed with non-reducing sample buffer. The Bio-Rad MiniGels (Hercules, CA) 
were run at 200 V for 1 hr. The PAGE gel was then either subjected to Western 
Blot or Coomassie Blue (0.1 % Coomassie Blue, 40 % MeOH, 10 % Acetic Acid 
and 50 % dH20) staining. For staining, gels were placed in Coomassie Blue 
stain overnight then destained for approximately 3 hours in Oestain (40 % MeOH, 
10 % Acetic Acid and 50 % dH20). Gels were then imaged using a Gel OOC™ 
XR+ System (Bio-Rad, Hercules, CA). 
After SOS-PAGE, western blots were utilized to confirm the presence of 
GST - aC (233 - 245) or determine whether all GST was removed after on-
column PreScission protease digestion. The gel, fiber pad, filter paper, and 
nitrocellulose membrane (NitroBind, Osmonics Inc.) were equilibrated by soaking 
them in the Western Blot Transfer Buffer (25 mM Tris, 192 mM Glycine and 20 % 
MeOH pH=8.3) for 15-20 min at room temperature. The Mini Trans-Blot (Bio-
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Rad Hercules, CA) was loaded as per instructions and run at 100 V for 1 Hr at 4 
DC. To decrease non-specific binding, the nitrocellulose membrane was placed 
in a 3 % BSA Blocking Solution in PBST with stirring overnight at room 
temperature. The following morning, the membrane was washed in PBST then 
placed in a solution containing 1 :5000 a-GST-HRP (horseradish peroxidase) (GE 
Healthcare, Piscataway, NJ). After a series of 5 rinses in 1 x PBST, the 
membrane was developed using 1-Step TMB-Blotting solution, a blue TMB 
(3,3',5,5'-tetramethylbenzidine) peroxidase which is an HRP substrate (Pierce, 
Rockford, IL). Membranes were then dried and visualized on the Gel OOC™ XR+ 
System (Bio-Rad, Hercules, CA). 
15N_1H HSQC 
After the 15N labeled and unlabeled aC domain (233 - 425) were dialyzed 
and concentrated, they were loaded into NMR Shigemi tubes. The concentration 
in the NMR ranged from < 100 I-IM for the unlabeled aC domain (233 - 425) to > 
200 I-IM for the 15N labeled material and all samples were run in the presence of 
10 % 0 20. The pH of NMR samples was not adjusted below 6.6 due to a 
theoretical pi of 6.28 (http://web.expasy.org/protparam/). Two NMR experiments 
were run to establish the feasibility of determining aC domain (233 - 425) 
structure. aC domain (233 - 425) was first analyzed with a Watergate 1 H-
TOSCY and then the 15N_aC domain (233 - 425) was utilized in 15N_1H HSQC. 
To determine if the aC domain (233 - 425) adopts a defined compact structure in 
the presence of FXIII-A2 a 15N_1H HSQC was performed. For this analysis, 350 
1-11 of 210 I-IM 15N aC (233 - 425) was used to solubilize 3.2 mg dialyzed and 
lyophilized FXIII-A2. The final concentrations in the NMR tube were 110 I-IM 
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FXIII-A2 and 210 IJM 15N aC (233 - 425). All NMR experiments were performed 
on a 16.4 Tesla 700 Varian Inova MHz NMR or an 18.8 Tesla 800 MHz Varian 
Inova NMR. 
The NMR data shown in Chapter V were collected on the Varian Inova 
800 MHz spectrometer which is equipped with a triple resonance probe and 
pulsed-field triple axis gradients. 1H - 15N HSQC experiments were run on the 
15N aC (233-425) in the absence and presence of unlabeled FXIII A2. For both 
systems, the 1H frequency was 799.708 Hz and the sweep width was set at 
12000 whereas the 15N frequency was 81.043 Hz and the sweep width was set at 
2300. Spectra were collected with 1800 complex points in the 1 H dimension and 
100 increments in the 15N dimension. The number of transients was 8. All HSQC 
experiments were run at 20°C and water was used as a reference. The NMR 
data were processed using NMRPipe and NMRDraw version 6.5 (123) and the 
results visualized using Sparky version 3.1 (124). The ppm reference for the 
center of both 20 spectra was 4.821 ppm and 119.990 ppm. Sparky was also 
used to overlay the HSQC spectrum of 15N aC (233-425) on to the spectrum of 
the protein-protein complex involving 15N aC (233-425) and FXIII A2. The Overlay 
Views dialog box was used. Both spectra had been subjected to the same 
experimental parameters, referencing, and data processing strategies. 
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Results 
aC (233 - 425) Expression in LB Broth 
To establish an expression system in the lab two systems were chosen for 
method development, FXIII-A2 and aC (233 - 425) . The aC (233-425) gene was 
cloned into pGEX-6P-1 vectors (Figure 38) . The location of the aC gene insert 
was ideal for PreScission protesase cleavage and GST cleavage during 
pu rification . 
The first objective was to transform the cloned pGEX-6P-1 vector into 
Elem,=nt:12 
Mn f()NIard20 primer 
- Element#11 
M13 pUC rev primer 
- Elememt#1 0 
lacl 
















Figure 38: Map of pGEX-6P· 1 vector. Elements of interest are labeled. The elements to note are the 
tacJ)romotor (Orange) , GST-tag which contains the pGEX-5' primer (Blue) , alpha_C gene (Red) . 
pGEX_3_primer and the Ampicillin gene (Purple) . Image created using DNA 2.0 Gene Designer 2.0 software. 
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DH5a cells in order to build a series of DNA stocks. Using the transformation 
methods set forth by Smith et. al., the DNA yields from a standard MiniPrep were 
consistently 60-80 ng/ml (121). This allowed for the storage of several DNA 
aliquots to be used in future studies. To confirm that the purified DNA contained 
the aC (233 - 425) gene, it was sequenced using the pGEX-6P-1 3' and 5' 
Query 1 ACAGACATGCCGCAGATGAGAATGGAGTTAGAGAGACCTGGTGGAAATGAGATTACTCGA 60 
111111111111111111111111111111111111 1 11111111111111111111111 
Sbjct 634 ACAGACATGCCGCAGATGAGAATGGAGTTAGAGAGACCTGGTGGAAATGAGATTACTCGA 575 
Query 61 GGAGGCTCCACCTCTTATGGAACCGGATCAGAGACGGAAAGCCCCAGGAACCCTAGCAGT 120 
1111111111111111111111111111111 1 1111 1 11111111111111111111111 
Sbjct 574 GGAGGCTCCACCTCTTATGGAACCGGATCAGAGACGGAAAGCCCCAGGAACCCTAGCAGT 515 
Query 121 GCTGGAAGCTGGAACTCTGGGAGCTCTGGACCTGGAAGTACTGGAAACCGAAACCCTGGG 180 
1111111111111111111111111111111 1 1111 1 11111111111111111111111 
Sbjct 514 GCTGGAAGCTGGAACTCTGGGAGCTCTGGACCTGGAAGTACTGGAAACCGAAACCCTGGG 455 
Query 181 AGCTCTGGGACTGGAGGGACTGCAACCTGGAAACCTGGGAGCTCTGGACCTGGAAGTGCT 240 
1 1 11111111111111111111111111111 1 1111 1 11111111111 1 11111111111 
Sbjct 454 AGCTCTGGGACTGGAGGGACTGCAACCTGGAAACCTGGGAGCTCTGGACCTGGAAGTGCT 395 
Query 241 GGAAGCTGGAACTCTGGGAGCTCTGGAACTGGAAGTACTGGAAACCAAAACCCTGGAAGT 300 
1111111111111111111111111111111 1 1111 1 11111111111 1 11111II II 
Sbjct 394 GGAAGCTGGAACTCTGGGAGCTCTGGAACTGGAAGTACTGGAAACCAAAACCCTGGGAGC 335 
Query 301 CCTAGACCTGGTAGTACCGGAACCTGGAATCCTGGCAGCTCTGAACGCGGAAGTGCTGGG 360 
1 1 11111111111111111111111111111 1 1111 1 11111111111 1 11111111111 
Sbjct 334 CCTAGACCTGGTAGTACCGGAACCTGGAATCCTGGCAGCTCTGAACGCGGAAGTGCTGGG 275 
Query 361 CACTGGACCTCTGAGAGCTCTGTATCTGGTAGTACTGGACAATGGCACTCTGAATCTGGA 420 
1 1 11111111111111111111111111111 1 1111 1 11111111111 1 11111111111 
Sbjct 274 CACTGGACCTCTGAGAGCTCTGTATCTGGTAGTACTGGACAATGGCACTCTGAATCTGGA 215 
Query 421 AGTTTTAGGCCAGATAGCCCAGGCTCTGGGAACGCGAGGCCTAACAACCCAGACTGGGGC 480 
1 1 1 1 11111111111111111111111111 1 1 1111 1 11111111111 1 11111111111 
Sbjct 214 AGTTTTAGGCCAGATAGCCCAGGCTCTGGGAACGCGAGGCCTAACAACCCAGACTGGGGC 155 
Query 481 ACATTTGAAGAGGTGTCAGGAAATGTAAGTCCAGGGACAAGGAGAGAGTACCACACAGAA 540 
1 1 11111111111111111111111111111 1 1111 1 11111111111111111111111 
Sbjct 154 ACATTTGAAGAGGTGTCAGGAAATGTAAGTCCAGGGACAAGGAGAGAGTACCACACAGAA 95 
Query 541 AAACTGGTCACTTCTAAAGGAGATAAAGAGCTCAGGACT 579 
1 1 1 1 111111111111111111111111111 1 1111 1 11 
Sbjct 94 AAACTGGTCACTTCTAAAGGAGATAAAGAGCTCAGGACT 56 
Figure 39: Alignment of 3' primer sequence data (top) and aC (233 - 425) gene sequence (bottom) . 
primers (3' CCGGGAGCTGCATGTGTCAGAGG and 5' 
GGGCTGGCAAGCCACGTTTGGTG) (Figure 38). Both the 5' and 3' primers 
produced sequence data that confirmed the entire aC (233 - 245) construct 
sequence (Figure 39) . The two mis-hits (nucleotide 297 and 300) in Figure 39 
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were both mutations that did not lead to a change in amino acid. The G to A 
(GG(A)) mutation at nucleotide 297 remains a glycine and the C to T (AG(T)) 
mutation at nucleotide 300 remains a serine. 
Initially, protein expression took place in standard LB media. The DNA 
collected from DH5a cells was successfully transformed into BL21 Gold (DE3) 
cells. During the first attempts at collecting purified protein from a 2 L culture, the 
decision was made to elute the uncleaved GST-aC (233 - 425) from the GSTrap 
column. The next step was developing a method to release the GST from the aC 
(233 - 425). This was done via an on-column digest (Figure 37) which utilized 
PreScission protease. PreScission protease selectively cleaves between Gin 
and Gly in a sequence (Leu Glu Val Leu Phe Gin I Gly Pro) found N-terminally to 
aC (233 - 425). Therefore, after 
transformation and purification the cell 
extract was loaded on the GSTrap column 
and then the column was removed from 
the AKTAprime system. At which time 
PreScission protease was added and 
incubated on-column overnight at 4 °c to 
allow for cleavage between aC (233 - 425) 
MW = 19582 g/mol and GST MW = 27,000 
g/mol. The GST and GST -tagged 
PreScission protesase remain on the 
columan and the cleaved aC (233 - 425) 
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Figure 40: Representative GST specific 
Western Blot. Lane (1) was collected from 
the waste line while loading the column with 
cell extract. (2) was the cell extract. (3) was 
the concentrated aC product with GST 
contaminant. (4) was the ladder. (5 and 6) 
were collected during GST elution . 
was eluted the following morning . SOS-PAGE and a GST-specific western blot 
were run to evaluate the expression and purification process (Figure 40). The 
GST-specific western blot exposed that GST was eluting with the aC (233 - 425); 
therefore, in future protein elutions an additional GSTrap column was added post 
on-column digestion to sequester any GST that may be co-eluting with aC (233 -
425). 
A B 
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Figure 41: Representative SOS-PAGE and western blot confirming proper aC (233 - 425) purification 
and GST cleavage. (A) The first three wells in the SOS-PAGE illustrate the aC (233 - 425) was 
sufficiently cleaved and eluted. The GST elution illustrated in wells 5 - 7 demonstrated minimal residual 
aC (233 - 425) . This carryover was not affected by increasing the column wash-time/volume between 
aC (233 - 425) and GST elution. (8) Wells 1 - 3 of the GST-specific western blot demonstrated a clean 
aC (233 - 425) elution free from GST. Wells 5 - 7 contain the cleaved GST fraction . 
Expresssion in minimal media 
Expression in minimal media proved to be just as successful as aC (233 -
425) expression in under standard nutrient conditions. The true yields of both LB 
and minimal media expressions are difficult to report due to loss of material 
during storage, dialysis, and surfactant removal but both methods were 
successful in producing enough protein for NMR analysis. During minimal media 
expression and purification , the GST that had eluted with purified aC (233 - 425) 
previously was eliminated (Figure 41 B). One issue that did occur in all 
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expressions was mild carryover after aC (233 - 425) elution. The aC (233 - 425) 
that eluted with the GST was seen as a faint band around 20 kDa in the GST 
fractions (Figure 41A). This band occurred even after increasing the column 
wash time following aC (233 - 425) elution. Another possible issue is the band in 
the western blot around 45 kDa. This could possibly be conjugated GST-aC (mw 
= 46,582 kDa). If that were the case, additional PreScission protease should 
yield more aC (233 - 425) and decrease the intensity of the band at 45 kDa. This 
was attempted and the 45 kDa band was still quite prominent; therefore, the 
large band around 45 kDa may be due to non-specific binding. The aC (233 -
425) expression system proved to be quite versatile and allowed for protein 
production under standard nutrient conditions and under minimal media with 15N_ 
NH4CI. 
aC (233 - 425) 15N-HSQC 
Although the ultimate goal of expressing aC (233 - 425) in 15N-labeled 
minimal media was to enable NMR observations, the first NMR experiments 
utilized unlabeled aC (233 - 425). A valuable lesson was learned during our first 
TOSCY analysis of unlabeled aC (233 - 425). There was substantial 
contamination from a small molecule in our sample. After reviewing the 
purification procedures, the problem was identified as Triton X-100 which is 
added to help solubilize the protein before centrifugation. The Triton X-100 
concentration is 1 % and the critical micelle concentration is 0.1 %. The Triton X-
100 micelles contain 628 Triton units/micelle therefore has an apparent 
molecular weight of -90 kDa. This apparent molecular weight caused the Triton 
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Figure 42: 15N_HSQC spectra of 15N_aC (233-425) conducted on an 800 MHz (18 T) Varian Inova NMR at 
20 °C. The assignments can be viewd in appendix F. 
X-100 to concentrate with our protein of interest. In order to thwart this problem 
in the future two different techniques were utilized , 10,000 MWCO dialysis into 1 
x PBS and/or Detergent Removal Spin Columns. 
The first 15N-HSQC spectra for 15N_ aC (233 - 425) were attained on a 
16.4 T Varian NMR equipped with a triple resonance cryoprobe and confirmed on 
the 18 T Varian NMR (Figure 42) . The concentration of aC (233 - 425) was 210 
IJM and pH = 6.6. As this was an aqueous sample, Watergate was utilized for 
water suppression. These experiments prove that even at sub mM 
concentrations of aC (233 - 425) one can still observe the 1 H_15N-HSQC 
transitions. aC (233 - 425) contains 193 residues, 17 of which are proline, so 
therefore there are 176 amide hydrogens. In addition to the amide backbone, 
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there are 13 asparagines, 3 glutamines (each with two proton signals for the 
same nitrogen) and 7 tryptophans. Therefore, there should be a total of 199 
observable 15N_1H signals. The aC (233 - 425) 15N-HSQC successfully identified 
approximately 184 of the 199 possible signals (Appendix F) . Of the 7 Trp all but 
one was visible and 13 of the 19 Asn and Gin were visible . 
Once an HSQC for aC (233 - 425) was established, the next goal was to 
observe aC (233 - 425) in the presence of FXIII-A2 (Figure 43). The same 210 
!-1M aC (233 - 425) sample used previously was utilized to solubilize 3.2 mg 
FXIII-A2. The sample precipitated out of solution and sonication for 5 min at 
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Figure 43: 15N_HSQC spectra of 15N_aC (233-425) in the presence of FXIII-A2 conducted at 20 ·C on an 
800 MHz (18 T) Varian Inova NMR. The assignments can be viewed in Appendix G. 
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room temperature did not increase solubility. The pH of the aC (233 - 425) -
FXIII-A2 solution was confirmed to be 6.6 and was spun at 14,000 rpm. The 
supernatant was then transferred to a Shigemi tube for NMR analysis. Due to 
precipitation and analysis of the supernatant the final concentration of aC and 
FXIII-A2 was unknown, but assumed to be less than the starting concentrations 
(210 ~M and 110 ~M respectively). The structure of aC (233 - 425) in the 
presence of FXIII-A2 was also investigated using an 18 T Varian NMR. When 
aligned with the 15N_aC (233 - 425) 1H_15N_HSQC, 15N_aC (233 - 425) with FXIII-
A2 did not exhibit any major peak shifts but several new peaks appeared. In the 
HSQC for aC (233 - 425) in the presence of FXIII-A2, approximately 191 of the 
199 possible N-H stretches were observed (Appendix G). This was an increase 
of 7 over the 184 signals observed for aC (233 - 425). The most notable new 
peaks are at (N-120.7 ppm, H-8.68 ppm) and (N-121.8 ppm, H-8.36 ppm) as well 
as the Trp residue (N-129.7 ppm, H-10.15 ppm). It is quite promising to see that 
even under conditions where some material may have been lost during 
precipitation, aC (233 - 425) still appears to gain some structure when in the 
presence of FXIII-A2. 
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Discussion 
Many kinetic and conformational dynamic studies require specific 
mutations. Thus it is imperative to establish and maintain functional expression 
systems. The aC (233 - 425) DNA that was given to our lab has now been 
successfully transformed into both DH5a and BL21 DE3 (gold) E. coli cells. The 
transformed DNA was then utilized to express and purify aC (233 - 425) for 15N_ 
HSQC NMR analysis. 
aC (233 - 425) Expression 
The DNA utilized had the aC (233 - 425) gene cloned into a pGEX-6P-1 
vector. The pGEX-6P-1 vector has several benefits. Expression of aC (233 -
425) in the pGEX-6P-1 vector is induced with IPTG. aC (233 - 425) expression 
is under the control of the tac promoter which is induced by IPTG, a lactose 
mimic. The pGEX-6P-1 plasmid also contains a lacf1 gene which produces a 
repressor for the tac gene inhibiting expression untillPTG is added. To ease in 
protein purification following expression, the protein of interest is co-expressed 
with a GST tag. The GST tag is then subsequently utilized in affinity 
chromatography to capture the GST-aC product. Another benefit of the pGEX-
6P-1 is that it contains an Ampicillin resistance gene to assist in confirming 
transformation in your cells of interest. 
Two different cell lines were chosen for aC expression, the first of which 
was DH5a. The DH5a cells chosen were the Subcloning Efficiency Competent 
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Cells which allowed for an efficient transformation and subsequent production of 
purified DNA for future transformations. One lesson learned during this process 
was that if the transformation does not produce nice round colonies and the 
plates are covered with a lawn of E coli, the Ampicillin may have expired. 
According to Ryan, et al. Ampicillin starts to lose activity after 30 days at 4 °C 
(125). Following expression in DH5a cells the DNA that had been successfully 
purified was transformed into BL21 cells for aC (233 - 425) expression and 
purification. 
The E coli strain BL21 gold (DE3) is frequently used as a host for protein 
expression studies. Bhandari and Gowrishankar reported on the robustness of 
the BL21 gold expression options (126). BL21 cells also limit the degradation of 
expressed proteins because they naturally lack genes for the proteases Ion and 
ompT (127). Although transformation efficiency was never calculated, a nice 
selection of colonies was always observed. The reported efficiency for pUC18 
DNA is ~ 1 x 108 cfu (colony forming units)/lJg of DNA (Stratagene, La Jolla, CA). 
Once transformed into the BL21 gold cells, selected colonies were then 
grown in liquid LB broth to create glycerol stocks of cells ready for aC (233 -
425) expression. The glycerol stocks were stored at -70°C and a sterile loop 
was utilized to seed cultures for expression. After an overnight incubation, the 
starter culture was utilized to seed a larger (1-2 L) culture. There are several 
variables which are critical to maximizing the amount of aC (233 - 425) 
expressed, one of which is the proper cell density for induction. During log 
phase, the doubling time of Ecoli is typically between 20 - 30 min in nutrient rich 
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media. It is during this time that cells are in the optimal condition for expressing 
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Figure 44: Theoretical E. coli growth curve. Lag phase displays the slow growth after inoculation. 
During Log Phase, the cell doubling time is around 20 - 30 min. This is the optimal time for induction of 
protein expression. During stationary phase, nutrients are limited, cells become stressed and protein 
degradation can occur. During death phase cells begin to die due to lack of nutrients and cell density 
decreased over time. 
protein (Figure 41) . During LB broth, nutrient rich , expressions the cells were 
induced at A600 = 1.0 and 0.6 for the minimal media expressions. The slope 
during log phase decreased from 0.54 A6oo/hour for growth in nutrient rich media 
to 0.20 A6oo/hour in minimal media. This> 2.5 fold decrease in slope led to much 
longer incubation times prior to induction for the minimal media expressions. 
To ensure induction during log phase, the induction for minimal media 
took place at A600 = 0.6 since nutrient rich growth appears to be approaching 
stationary phase when A600 = 1.0 (Figure 42) . After IPTG addition both nutrient 
rich and minimal media cultures were allowed to incubate overnight at 30 ac. 
This is another variable which could possibly be optimized. By decreasing the 
rpm of the shaker from 225 to 180 rpm and decreasing the temperature from 37 
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°C to 30 °C, it slows the growth. It may be worth investigating shorter induction 
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Figure 45: Representative growth curves for BL21 gold (OE3) cells grown in LB broth and minimal 
media. LB Broth is represented by the (Red Squares) and the time points utilized for calculating the 
slope of the Log Phase are marked with a black (X) . The minimal media growth curve is represented by 
(blue diamonds) and the time points utilized for calculating the slope of the Log Phase are marked with a 
black (X) . 
overcome involved the use of Triton-1 00 during the purification process. When 
viewing the first aC (233 - 425) NMR Triton X100 was the only molecule visible. 
The Triton X100 was concentrated when using 10,000 MWCO centrifuge 
concentrators to purify the aC (233 - 425) . To thwart this in future aC (233 -
425) expressions, both detergent removal spin columns and dialysis were utilized 
successfully. Further experimentation could be performed to determine which 
process is the most effective. 
aC (233 - 425) 15N_HSQC 
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It was first reported in 1981 that the 242-424 region of the fibrinogen a-
chain was involved in reducing the concentration of Ca2+ needed for FXIII-A2 to 
dissociate from FXIII-B2 (74). Until recently very little research has been 
dedicated to further investigating this interaction between the aC-domain (C-
terminal portion of the fibrin a-chain) and FXIII-A2. There have been a series of 
manuscripts which have focused on determining whether bovine and/or human 
aC-domain contains compact structure (102, 113, 128). Burton et al. utilized 
NMR to identify and characterize a ~-hairpin with a disulfide (C423-C453) 
restricting the base in bovine aC (374 - 538) (102). The ~-hairpin was then 
further characterized with a shorter aC fragment (406 - 483) focusing in on the 
compact structure (113). During this study aC (406 - 483) was fully 
characterized by NMR which allowed for the identification of a second loose ~­
hairpin that is formed by residues 459 - 476. It was also determined by size 
exclusion chromatography and analytical ultracentrifugation that the aC (406 -
483) fragment formed oligomers in a concentration dependant manner, starting 
at concentrations as low as 3 mg/ml (113). 
More recently, the knowledge gained from investigating the structure of 
bovine aC has been utilized to better understand human aC structure. It was 
determined that human aC (425 - 503) and (392 - 610) form oligomers as a 
function of concentration like their bovine counterparts (128). The NMR analysis 
of human aC (425 - 503), equivalent to bovine (406 - 483), was limited due to 
the oligomerization. Since bovine aC (406 - 483) had been fully characterized, 
the human aC 15N_HSQC was compared to the bovine. This comparison 
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revealed that human aC (425 - 503) contained several of the same peakes that 
were essential for l3-hairpin formation in bovine aC (113, 128). 
These human aC structural studies utilizing NMR have yet to describe 
how aC interacts with FXIII. Smith et al. has extensively studied the human aC 
(233 - 425) fragment and how it interacts with unactivated FXIII-A2, activated 
FXIII-A2 and FXIII-A2B2 (121) . Surface plasmon resonance (SPR) was used to 
study a series of truncated aC fragments and it was determined that activated 
10 
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Figure 46: 15N_HSQC spectra of 15N_aC (233-425) overlaid on the spectra for 15N_aC (233-425) in the 
presence of FXIII-A2. The 15N_HSQC spectrum for aC (233-425) is displayed in ~Iue) and aC (233-425) in 
the presence of FXIII-A2 in (pink) . The three peaks noted are only visible in the 1 N-HSQC spectra for aC 
(233-425) with FXIII-A2.The image was produced using the overlay command within Sparky 3 (124) . 
FXIII-A2 had low !-1M affinity for aC and it was localized to residues 389 - 403. 
FXIII- A2B2 was found to have low nM affinity and surprisingly, FXIII-A2 zymogen 
did not bind to any of the aC fragments (121). The 15N-HSQC data reported here 
investigates aC (233 - 425) both in the presence and absence of FXIII-A2 
zymogen. After the addition of aC to the lyophilized FXIII-A2 there was a 
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substantial amount of precipitate formed. It is unknown whether the precipitate 
correlates to aC oligomerization or possible aC-FXIII-A2 interactions. The 
sample for aC with FXIII-A2 15N-HSQC analysis had to be spun down and only 
the supernatant was analyzed. The increase in total peaks identified for the aC 
(233 - 425) with FXIII-A2, as seen in the overlay of the two spectra, alludes to an 
interaction that induces structure in aC (Figure 46). Our lab has now established 
an aC (233 - 425) expression system in standard media as well as minimal 
media capable of producing enough protein for NMR analysis. These NMR 
studies have now opened the door to further investigation of aC (233 - 425) in 
the presence of FXIII-A2. 
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CHAPTER VI 
CONCLUSIONS AND FUTURE DIRECTIONS 
Factor XIII is one of the last enzymes involved in the blood coagulation 
cascade and is responsible for cross-linking fibrin monomers to form an insoluble 
clot. Through the utilization of HDX coupled with MALDI-TOF MS, great strides 
have been made in clarifying FXIII-A2 conformational dynamics during activation. 
The importance of FXIII during haemostasis has led to increased interest in 
acquiring a greater understanding of how this enzyme interacts with its 
substrates and cofactors in solution. Therefore, in addition to studying FXIII, 
NMR was utilized to investigate the FXIII-A2 substrate fibrin aC (233-425). 
The conformational dynamics of Factor XIII-A2 (zymogen, FXlllalla , 
FXlllaca, and inhibited with Kg-Don) in solution has been extensively studied 
using HDX (43, 45-46). One area that lacked understanding was how the FXIII-
A2 structure was dependent upon physiological Ca2+ concentrations. Chapter II 
describes the first objective of this project; to investigate the conformational 
dynamics of FXIII-A2 under physiological Ca2+ concentrations and compare to 
other metals of interest (Mg2+, 8a2+, and Cu2+). HDX analysis identified regions 
of FXIII-A2 where Ca2+ elicited unique conformational differences when compared 
to the other metals studied. There were also several regions of FXIII-A2 where all 
metals examined yielded similar conformational changes. Due to the similarities 
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observed for these metals, they were then tested to determine whether they 
could promote non -proteolytic FXIII-A2 activity. 
In addition to studying FXIII-A2 non-proteolytic activation in the presence 
of 50 mM Ca2+, Mg2+, 8a2+ and Cu2+, we also investigated 500 mM Na+ and two 
organic cations EDA2+ and TMAC+. When investigating each cation individually 
only 50 mM Ca2+ could promote FXIII-A2 activity. The cations Mg2+, 8a2+, Na+, 
EDA2+ and TMAC+ all induced FXIII-A2 activity when in the presence of 2 mM 
Ca2+. Low mM Ca2+ was essential for non-proteolytic activation. The activity 
observed using organic cations (EDA2+ and TMAC+) revealed that non-proteolytic 
activation is not unique to metal ions (44). HDX analysis was then utilized to 
study the conformational dynamics of non-proteolytically activated FXIII-A2. 
These analyses revealed that exposure around the active site and substrate 
recognition regions was initiated by physiological Ca2+ concentrations and set the 
stage for the larger conformational changes observed after activation. 
While working on the FXIII-A2 conformational dynamics presented in 
Chapter II, Pinkas et al. reported that TG2 is trapped in an open conformation 
when bound to a substrate-based inhibitor (49). It has been debated whether 
FXIII-A2 undergoes a similar conformational change; therefore, in Chapter III 
HDX was utilized to compare the solvent accessibility of TG2 zymogen to that of 
activated TG2 and also inhibited TG2. Evidence of the open conformation was 
observed as increased exposure on the p-barrels and regions of the catalytic 
core. When comparing FXIII-A2 to the open conformation of TG2 it becomes 
obvious that in order to exist in an open conformation, FXIII-A2 must overcome 
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substantial steric strain between the ~-sandwich of one FXIII-A2 monomer and ~­
barrel 2 of the opposing monomer. If FXIII-A2 does adopt an open conformation, 
it could lead to further developments in pharmaceuticals and antibodies specific 
for the open conformation which could be utilized in correcting aberrant FXIII-A 
during coagulation. 
In regards to comparing TG2 and FXIII-A2 conformational dynamics, future 
work could take a few directions. Y238C FXIII, a physiological mutant, is a 
monomer. Now that our lab has established expression systems, it may be 
possible to express FXIII-A Y283C and compare FXIII-A in the monomer form to 
TG2. The Y283C monomer would be utilized because, as mentioned in Chapter 
III, the 'open' conformation seen in TG2 may be sterically impossible for the 
FXIII-A2 dimer. Although the Y283C mutant is physiological, it is not stable in 
whole plasma, having a shorter t1l2 than wild type FXIII (99). If the Y283C mutant 
shows promise, mutation of the homologous TG2 residues may create a stable 
monomer, which one day might be used as a therapeutic for FXIII deficiency and 
thus combat postoperative bleeding 
After exploring FXIII-A2 during activation and comparing FXIII-A2 to the 
open versus closed conformation for TG2, our focus shifted in Chapter IV to the 
conformational dynamics of FXIII-A2 bound to FXIII-B2 but before activation. It 
has been proposed that the two ~-barrels of FXIII-A2 interact with FXIII-B2 in the 
heterotetramer since heterotetramer formation does not occur when the ~-barrels 
are truncated (99). This evidence is supported by the significant protection from 
HDX observed in the ~-barrels. If the FXIII-B2 dimer assumes the structure 
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proposed by Souri, et 81. its length would be> 380 A (98). The FXIII-A2 structure 
is only 102 A in length, and therefore, protection was observed throughout FXIII-
A2. One FXIII-A2 region of interest during activation, the dimer interface, 
becomes significantly protected when bound to FXIII-B2, which would limit FXIII-
A2 activation. 
To further investigate the FXIII-A2B2 heterotetramer, a more intensive HDX 
method could be performed. Our MALDI-TOF MS method works well, but 
increased sensitivity and increased sequence coverage is observed using LC-
ICR-MS (129-130). Develop an HDX method on an LC-FT-ICR-MS would open 
many new doors. Historically, LC methods were avoided during HDX 
experimentation due to increased hydrogen back-exchange during the aqueous 
separation prior to MS detection. This problem is now avoided by keeping the 
column and transfer lines chilled to 0 °C and also the advances in LC and column 
technology that have led to shorter run times (1 min). One factor limiting HDX 
with MALDI-TOF-MS detection is the mass of the protein and number of proteins 
being analyzed due to the increase in peptides produced and the inability to 
distinguish them. A liquid chromatography separation of peptides prior to MS 
detection allows for the identification of peptides of similar mass that overlap in a 
MALDI-MS. 
Now that the regions of FXIII-A2 which contact FXIII-B2 in the FXIII-A2B2 
heterotetramer have been established, it would be of interest to utilize NMR to 
determine the regions of aC(233 - 425) that contact on FXIII-A2B2. The aC(233 
- 425) region is involved in the dissociation of FXIII-A2 and FXIII-B2, and may 
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adopt a unique conformation when interacting with the FXIII-A2B2 heterotetramer. 
It would be nice to compare the analysis of aC(233 - 425) in the presence of 
FXIII-A2B2 to the results reported in chapter V for aC(233 - 425) in the presence 
of FXIII-A2. 
Lastly, in chapter V, a method was established for expressing aC (233 -
425) in both standard LB broth for bulk protein production and minimal media for 
isotopically labeling the protein to enable NMR analysis. The aC (233 - 425) 
domain was chosen because of its known involvement in fibrin crosslinking by 
FXIII-A2. Not only does aC (233 - 425) contain 3 FXIII-A2 Gin substrate 
residues, it also acts as a cofactor in the dissociation of FXIII-A2B2 as well (74, 
109). The aC (233 - 425) region is largely unstructured and has yet to be 
visualized via crystallography (110-111). 
In an attempt to determine if the aC (233 - 425) region adopts a compact 
structure when interacting with FXIII-A2, 15N_aC (233 - 425) was expressed in 
minimal medial and subjected to 15N-HSQC NMR analysis. An increase in the 
total number of peaks indicates that the interaction between aC (233 - 425) and 
FXIII-A2 induces a more structured aC. While these NMR studies were being 
developed, Smith et al. used SPR techniques, to demonstrate that aC (233 -
425) has low nM affinity for FXIII-A2B2 and FXllla but does not interact with FXIII-
A2 zymogen (121). These results lead to the question of whether aC (233 - 425) 
adopts a more defined structure when interacting with activated FXIII-A2 or FXIII-
A2B2 versus the FXIII-A2 analyzed. 
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Once an aC (233 - 425) compact structure is defined, several different 
heteronuclear methods will be used to assign the HSQC spectrum. TOCSy-15N-
HSQC can be run with a singly labeled 15N_ aC-domain. Further analysis could 
be conducted with doubly labeled 13C_15N_ aC-(233 - 425). The benefit of the 
doubly labeled protein is the ability to determine sequential residues using HNCO 
and HN(CA)CO pulse sequences. For assigning more atoms in the amino acid 
side chains, other 30 experiments such as: HNCA, HN(CO)CA, HN(CA)CB and 
HN(COCA)CB can be used (131). 
To determine the structure, NOE assignments could then be elucidated 
using HSQC-NOESY, 15N_13C edited NOESY and 13C-13C-edited NOESY. The 
residual dipolar couplings (ROCs) of the amide backbone could be determined 
using 1H_15N IPAP-HSQC with and without Pfl phage for spin alignment (102). 
The NOE data gathered could then be entered into XPLOR-NIH (132) for 
structural calculations using the angle restraints calculated by TALOS (133). It 
would also be possible to determine the Kd of FXIII-A2 and aC(233 - 425) by 
titrating in FXIII-A2 and monitoring the shift in resonances for the residues that 
contact FXIII. TG2 could also be titrated in to determine if aC(233 - 425) 
interacts with the two transglutaminases differently. This comparison would aid 
in identifying differences in TG2 and FXIII substrate specificity. 
These studies have shed light upon the illusive FXIII conformational 
dynamics. This research presents a more global and functional understanding of 
how FXIII interacts with substrates and allosteric effectors like Ca2+ in solution. 
These discoveries may lead to better control of FXIII-A2 activity during 
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APPENDIX A: A DETAILED DIAGRAM OUTLINING THE BLOOD 
COAGULATION CASCADE 
Kindly provided by Abeam pic, Cambridge, England 
abeam-./'" 
Blood coagulation cascade 
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APPENDIX C: FXIII-A2 PEPTIC PEPTIDES 
Peptide m/za Amino Acid Sequence 
1-23 2431.30 SETSRTAFGGRRAVPPNNSNAAE 
32-40 926.15 QGVVPRGVN 
53-74 2819.06 FKERWDTNKVDHHTDKYENNKL 
75-82 963.03 IVRRGQSF 
83-99 2188.48 YVQIDFSRPYDPRRDLF 
88-98 1422.78 FSRPYDPRRDL 
100-111 1509.78 RVEYVIGRYPQE 
137-144 1031.09 REDRSVRL 
145-159 1682.03 SIQSSPKCIVG KFRM 
171-180 1177.20 RETSRNPETDT 
194-208 1930.10 YLDNEKEREEYVLND 
214-230 2051.24 YG EVNDI KTRSWSYGQF 
220-230 1372.70 IKTRSWSYGQF 
240-247 1014.09 YVMDRAQM 
248-264 1713.97 DLSGRGNPIKVSRVGSA 
248-265 1845.15 DLSGRGNPIKVSRVGSAM 
298-305 980.97 ILLEYRSS 
300-314 1800.83 LEYRSSE N PVRYGQC 
325-338 1589.88 LRCLGIPARIVTNY 
328-338 1217.36 LGIPARIVTNY 
364-372 1126.21 PVPIVSELQSG 
380-389 1133.28 MTRPDLPVGF 
407-424 1972.96 YRCGPASVQAIKHGHVCF 
513-522 1198.55 KSRSNVDMDF 
533-550 2213.56 FKLSITFRNNSHNRYTIT 
535-541 851.05 LSITFRN 
607-619 1534.65 FVTARINETRDVL 
632-646 1616.98 IIIKVRGTQVVGSDM 
a all m/z values represent the average mass of the undeuterated cluster. 
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APPENDIX D: TG2 PEPTIC PEPTIDES 
Peptide m/za Amino Acid Sequence 
12-25 2431.30 ELETNGRDHHTADL 
26-39 926.15 CREKLWRRGQPFW 
31-39 2819.06 VVRRGQPFW 
154-160 963.03 ERQEYVL 
237-253 2188.48 LGRWDNNYGDGVSPMSW 
259-269 1422.78 ILRRWKNHGCQ 
315-329 1509.78 FRNEFGEIQGDKSEM 
341-353 1031.09 MTRPDLQPGYEGW 
369-377 1682.03 CCGPVPVRA 
451-461 1177.20 EREAFTRANHL 
452-461 1930.10 REAFTRANHL 
475-487 2051.24 RIRVGQSMNMGSD 
502-508 1372.70 YVCRLLL 
547-554 1014.09 YEKYRDCL 
560-568 1713.97 IKVRALLVE 
668-686 1845.15 ESDKLKAVKG FRNVIIGPA 
a all m/z values represent the average mass of the undeuterated cluster. 
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APPENDIX E: LB BROTH AND LB AGAR RECIPES 
Table 1: 500 ml LB Broth 
5.0 9 Tryptone 
2.5 9 Yeast Extract 
5.0 9 NaCI 
Add 500 ml dH20 and stir to mix. pH the solution to 7.5 with 10 M NaOH and 
autoclave before use. If Ampicillin is needed, add prior to inoculation. 
Table 2: 500 ml LB Agar 
5.0 9 Tryptone 
2.5 9 Yeast Extract 
5.0 9 NaCI 
7.5 9 Agar 
Add 500 ml dH20 and stir to mix. pH the solution to 7.5 with 10M NaOH and 
autoclave. Let cool to -50°C and add 500 1-11100 mg/ml Ampicillin. Pour plates 
and allow them to cool at room temperature. Cap and store at 4°C. 
Table 3: 1 L SOB Medium 
20.0 9 Tryptone 
5.0 9 Yeast Extract 
0.5 9 NaCI 
Add 1 L dH20 and autoclave. After the SOB solution has cooled, add 10 ml filter 
sterilized 1 M MgCI2 and 10 ml filter sterilized 1 M MgS04 . 
Table 4: 1 L SOC Medium (make immediately before use) 
Add 2 ml filter sterilized 20 % glucose solution to 100 ml SOB Medium. 
Table 5: 1 L Phosphate Buffer 
23.2 9 KH2P04 
164 9 K2HP04 
Dilute to 1 L in volumetric flask. Transfer to autoclave safe bottle and autoclave. 
Table 6: 2 L Terrific Broth 
24.0 9 Tryptone 
48.0 9 Yeast Extract 
8 ml Glycerol 
Add 1.8 L of dH20 and autoclave. Before use add 200 ml Phosphate Buffer. 
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Appendix E (continued) 
Table 7: 1 L E. coli Wash Buffer 
20 ml 1 M Tris pH = 8 
10ml 5MNaGI 
Dilute to 1 L with dH20. 
Table 8: 1 L Phosphate Buffered Saline (1 x PBS) 
8.0 9 NaGI (137 mM) 
0.2 9 KGI (2.7 mM) 
1.42 9 Na2HP04 (10 mM) 
0.24 9 KH2P04 (2 mM) 
187.5 9 glycerol (15 %) 
Add 800 ml dH20 to the bottle and pH to 7.4 then fill to 1 L. Autoclave or filter 
sterilize before use. 
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APPENDIX F: NMR PEAKLIST FOR ac (233 - 425) 
assignment 15N ppm 1H ppm assignment 15N ppm 1H ppm 
112.288 7.488 41 122.081 8.541 
2 129.646 10.131 42 121.855 8.256 
3 129.613 10.099 43 121.761 8.393 
4 129.416 10.075 44 121.775 8.061 
5 129.358 10.147 45 121.583 8.226 
6 126.523 8.409 46 121.534 8.26 
7 125.876 8.3 47 121.481 8.337 
8 125.794 8.415 48 121.481 8.29 
9 125.606 8.387 49 121.333 8.438 
10 125.449 7.883 50 121.342 8.359 
11 124.919 8.207 51 121.318 7.916 
12 124.547 8.346 52 121.199 8.262 
13 124.393 8.177 53 121.146 8.554 
14 124.24 8.254 54 121.162 8.128 
15 124.107 8.292 55 121.097 8.5 
16 123.979 8.386 56 120.978 8.316 
17 123.884 8.416 57 120.813 8.15 
18 123.734 8.577 58 120.78 8.472 
19 123.634 8.253 59 120.731 8.52 
20 123.542 8.494 60 120.724 7.854 
21 123.342 8.164 61 120.724 7.844 
22 123.266 8.313 62 120.653 8.262 
23 123.229 8.437 63 120.49 8.443 
24 123.136 8.705 64 120.328 8.564 
25 123.073 8.402 65 119.935 8.095 
26 123.113 8.366 66 119.712 8.166 
27 122.928 8.721 67 119.491 8.036 
28 122.916 8.195 68 119.439 8.434 
29 122.867 8.237 69 119.189 8.263 
30 122.794 8.482 70 119.113 8.402 
31 122.801 8.271 71 118.949 8.366 
32 122.685 8.216 72 118.892 8.316 
33 122.661 8.443 73 118.813 8.403 
34 122.608 8.327 74 118.825 8.35 
35 122.566 8.6 75 118.781 8.29 
36 122.527 8.373 76 118.655 8.472 
37 122.358 8.298 77 118.56 8.501 
38 122.309 8.245 78 118.49 8.399 
39 122.262 8.577 79 118.085 8.223 
40 122.183 8.465 80 118.056 8.296 
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APPENDIX F (continued) 
assignment 15N ppm 1H ppm assignment 15N ppm 1H ppm 
81 117.93 8.437 121 113.028 6.93 
82 117.785 8.46 122 112.951 7.658 
83 117.67 8.268 123 112.946 7.499 
84 117.529 8.378 124 112.961 6.979 
85 117.445 8.204 125 112.9 7.62 
86 117.409 8.425 126 112.9 6.912 
87 116.908 8.058 127 112.863 7.602 
88 116.445 8.122 128 112.78 7.484 
89 116.373 8.304 129 112.771 7.474 
90 116.414 8.171 130 112.782 6.853 
91 116.084 8.312 131 112.751 7.586 
92 115.915 8.01 132 112.753 6.935 
93 115.809 8.284 133 112.616 7.494 
94 115.701 8.342 134 112.597 6.964 
95 115.703 8.209 135 112.569 6.864 
96 115.656 8.139 136 112.5 7.462 
97 115.618 8.173 137 112.234 6.937 
98 115.548 8.12 138 112.233 6.856 
99 115.494 8.084 139 111.791 8.619 
100 115.437 8.422 140 111.438 8.522 
101 115.268 8.313 141 111.424 8.534 
102 115.29 8.062 142 111.112 8.406 
103 115.172 8.27 143 111.099 8.368 
104 114.23 8.159 144 111.059 8.4 
105 114.144 7.987 145 110.806 8.527 
106 113.969 8.082 146 110.783 8.426 
107 113.768 8.139 147 110.802 8.393 
108 113.454 7.656 148 110.761 8.364 
109 113.451 6.979 149 110.412 8.242 
110 113.37 7.913 150 110.272 8.47 
111 113.313 7.261 151 110.317 8.195 
112 113.265 8.258 152 110.239 8.5 
113 113.264 8.087 153 110.139 8.568 
114 113.181 7.498 154 110.086 8.639 
115 113.174 6.948 155 110.029 8.206 
116 113.186 6.872 156 109.947 8.452 
117 113.092 8.177 157 109.852 8.374 
118 113.144 7.629 158 109.783 8.538 
119 113.129 6.961 159 109.709 8.596 
120 112.983 7.592 160 109.625 8.523 
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APPENDIX F (continued) 
assignment 15N ppm 1H ppm 
161 108.948 8.506 
162 108.918 8.472 
163 108.909 8.334 
164 108.823 8.358 
165 108.815 8.446 
166 107.949 8.267 
167 107.658 8.205 
168 132.122 8.078 
169 119.788 8.254 
170 113.171 7.322 
171 112.27 7.589 
172 129.965 10.091 
173 110.822 8.569 
174 110.805 8.669 
175 110.651 8.637 
176 115.748 8.46 
177 115.782 8.262 
178 121.697 8.432 
179 121.084 8.644 
180 121.578 8.608 
181 122.942 8.325 
182 113.242 7.19 
183 113.396 7.694 
184 129.669 10.078 
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APPENDIX G: NMR ASSIGNMENTS FOR aC(233 - 425) IN THE PRESENCE 
OF FXIII-A2 
assignment 15N ppm lH ppm assignment 15N ppm lH ppm 
111.454 8.522 40 122.615 8.327 
2 129.976 10.092 41 122.546 8.373 
3 129.693 10.154 42 122.37 8.297 
4 129.664 10.13 43 122.344 8.35 
5 129.684 10.075 44 122.319 8.246 
6 129.628 10.097 45 122.204 8.57 
7 129.425 10.074 46 122.168 8.465 
8 129.368 10.146 47 122.105 8.54 
9 126.534 8.409 48 121.869 8.258 
10 125.884 8.299 49 121.807 8.359 
11 125.802 8.414 50 121.792 8.061 
12 125.615 8.387 51 121.737 8.429 
13 125.458 7.883 52 121.777 8.394 
14 124.927 8.208 53 121.583 8.23 
15 124.561 8.346 54 121.558 8.612 
16 124.404 8.177 55 121.541 8.26 
17 124.251 8.253 56 121.499 8.339 
18 124.122 8.292 57 121.496 8.29 
19 124.001 8.385 58 121.427 8.554 
20 123.902 8.416 59 121.362 8.359 
21 123.742 8.576 60 121.347 8.438 
22 123.644 8.254 61 121.327 7.915 
23 123.559 8.493 62 121.214 8.264 
24 123.359 8.163 63 121.156 8.554 
25 123.332 8.188 64 121.17 8.131 
26 123.236 8.437 65 121.089 8.645 
27 123.278 8.312 66 121.107 8.5 
28 123.149 8.706 67 120.99 8.316 
29 123.152 8.367 68 120.822 8.149 
30 123.089 8.4 69 120.751 8.52 
31 122.939 8.72 70 120.789 8.472 
32 122.931 8.324 71 120.69 8.677 
33 122.924 8.195 72 120.732 7.853 
34 122.796 8.481 73 120.73 7.843 
35 122.835 8.27 74 120.665 8.261 
36 122.703 8.358 75 120.503 8.444 
37 122.723 8.218 76 120.339 8.564 
38 122.667 8.442 77 119.946 8.096 
39 122.568 8.601 78 119.806 8.255 
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APPENDIX G: (continued) 
assignment 15N ppm 1H ppm assignment 15N ppm 1H ppm 
79 119.722 8.166 118 115.084 8.264 
80 119.521 8.034 119 114.245 8.16 
81 119.45 8.433 120 114.156 7.987 
82 119.254 8.308 121 113.987 8.083 
83 119.204 8.265 122 113.778 8.139 
84 119.13 8.402 123 113.461 7.656 
85 118.96 8.366 124 113.448 6.979 
86 118.905 8.316 125 113.383 7.913 
87 118.821 8.403 126 113.383 7.693 
88 118.834 8.349 127 113.329 7.261 
89 118.772 8.291 128 113.273 8.258 
90 118.672 8.471 129 113.276 8.088 
91 118.586 8.5 130 113.21 7.195 
92 118.479 8.398 131 113.153 7.628 
93 118.102 8.224 132 113.184 7.497 
94 118.068 8.296 133 113.188 7.339 
95 117.966 8.435 134 113.192 6.87 
96 117.815 8.459 135 113.093 8.177 
97 117.683 8.269 136 113.143 6.961 
98 117.543 8.377 137 113.054 6.929 
99 117.435 8.424 138 112.979 7.591 
100 117.445 8.205 139 112.962 7.658 
101 116.921 8.059 140 112.961 7.497 
102 116.429 8.171 141 112.95 6.978 
103 116.456 8.122 142 112.912 7.619 
104 116.386 8.303 143 112.87 7.601 
105 115.934 8.01 144 112.914 6.911 
106 115.822 8.284 145 112.853 7.643 
107 115.791 8.262 146 112.769 7.585 
108 115.729 8.462 147 112.792 7.483 
109 115.719 8.342 148 112.78 7.471 
110 115.712 8.21 149 112.774 6.934 
111 115.641 8.138 150 112.793 6.853 
112 115.619 8.173 151 112.638 7.492 
113 115.548 8.12 152 112.617 6.964 
114 115.499 8.084 153 112.603 6.864 
115 115.452 8.422 154 112.513 7.46 
116 115.285 8.314 155 112.28 7.587 
117 115.295 8.061 156 112.263 7.486 
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APPENDIX G: (continued) 
assignment 15N ppm 1H ppm 
157 112.236 6.937 
158 112.247 6.855 
159 111.803 8.618 
160 111.438 8.534 
161 111.1 8.405 
162 111.111 8.367 
163 110.832 8.585 
164 110.818 8.569 
165 110.817 8.527 
166 110.823 8.393 
167 110.811 8.672 
168 110.793 8.425 
169 110.771 8.363 
170 110.654 8.64 
171 110.423 8.242 
172 110.324 8.194 
173 110.289 8.47 
174 110.258 8.5 
175 110.167 8.568 
176 110.102 8.639 
177 110.033 8.206 
178 109.955 8.451 
179 109.861 8.374 
180 109.792 8.537 
181 109.725 8.596 
182 109.61 8.522 
183 108.952 8.506 
184 108.918 8.471 
185 108.928 8.334 
186 108.827 8.446 
187 108.843 8.358 
188 107.952 8.266 
189 107.669 8.204 
190 113.158 6.947 
191 132.113 8.077 
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APPENDIX H: ABBREVIATIONS 
(Not defined in coagulation schematic and in alphabetical order) 
1 D- One Dimensional 
2D- Two Dimensional 
a2AP- a2-antiplasmin 
a-CHCA- a-cyano-4-hydroxycinnamic acid 
AP- Activation Peptide 
AUC- Analytical Ultracentrifugation 
DMSO- Dimethylsulfoxide 
DON- 6-diazo-5-oxo-norleucine 
FXllla"a- Thrombin Activated FXIII 
FXlllaca_ Calcium Activated FXIII 
GDH- Glutamate Dehydrogenase 
GDP- Guanine Diphosphate 
GEE- Glycine ethyl ester 
HDX- Hydrogen Deuterium Exchange 
HSQC- Heteronuclear Single Quantum Coherence 
IAA- lodoacetamide 
IC50- Concentration Resulting in 50% Inhibition 
IPAP- Inphase Antiphase 
Kd- Dissociation Equilibrium Constant 
MALDI- Matrix-Assisted Laser Desorption-Ionization 
MS- Mass Spectrometry 
MWCO- Molecular Weight Cut-Off 
mlz- Mass to Charge ratio 
NMR- Nuclear Magnetic Resonance 
NADH- Nicotinamide adenine dinucleotide 
TGase- Transglutaminase 
TG2- Transglutaminase 2 
TOF- Time-of-Flight 
TOCSY- Total Correlation Spectroscopy 
TFA- Trifluoroacetic acid 
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